2004

Citizen Coalition Denounces I-330: Insurance Lobby Initiative Seeks to Limit Patient Rights: PRNewswire - December 28, 2004; SEATTLE, Dec. 28 /PRNewswire/ -- Today, Citizens for Better Safer Healthcare, a coalition of consumer and patient rights groups, denounced Initiative 330 (I-330) -- an initiative backed by the insurance industry and the state medical association -- that would drastically limit the rights of patients across the state of
FDA Approves PRIALT(R) (ziconotide intrathecal infusion) for Severe Chronic Pain: Novel Non-Narcotic Treatment Based on Marine Snail Peptide Blocks Pain Signals: PRNewswire - December 28, 2004; -- PRIALT is Approved for Use Only in The Medtronic SynchroMed(R) EL, SynchroMed(R) II Infusion System and Simms Deltec Cadd Micro(R) External Microinfusion Device and Catheter NEW YORK, Dec. 28 /PRNewswire/ -- This is a MultiVu special report. There is a new alternative for patients who suffer from severe chronic pain
Kurt Salmon Associates Highlights 2004's Eight Significant Issues in the Health Care Industry: U.S. political landscape, flu vaccine shortage, and potholes in information superhighway: PRNewswire - December 28, 2004; NEW YORK, Dec. 28 /PRNewswire/ -- From the re-election of George W. Bush to the closure of key emergency rooms, significant moments in 2004 health care provider history will significantly shape the future of the U.S. health care industry, says Kurt Salmon Associates (KSA) Health Care Consulting Group. * Re-election of
FDA Issues Not Approvable Letter to Cellegy Pharmaceuticals for Cellegesic(TM): PRNewswire - December 23, 2004; SOUTH SAN FRANCISCO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY) announced that it received late today a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment). Cellegesic was the
Epimmune Provides Update on Cancer and HIV Clinical Development Programs: PRNewswire - December 21, 2004; SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today provided an update of ongoing clinical development programs with its EP-2101 therapeutic cancer vaccine and its EP-1090 therapeutic HIV vaccine. Cancer Vaccine Clinical Development Epimmune conducted two Phase 1 clinical trials of its EP-21
Former Regional Director for Sales for Serono Laboratories, Inc. Pleads Guilty to Offering Kickbacks to Doctors, Reports U.S. Attorney: PRNewswire - December 21, 2004; BOSTON, Mass., Dec. 21 /PRNewswire/ -- A Hewlett, New York man pleaded guilty today in federal court to offering kickbacks to three New York City doctors by offering them an all expenses paid trip to attend a medical conference in Cannes, France in April of 1999, in return for writing prescriptions of Serostim, a brand
Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines: First Collaboration to Develop a Once-Daily Antiretroviral Fixed-Dose Regimen: PRNewswire - December 20, 2004; NEW YORK and FOSTER CITY, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences , Inc. (Nasdaq: GILD) today announced details of a joint venture to develop and commercialize the fixed-dose combination of Bristol-Myers Squibb s
AIDS Action Committee Manages Utility Assistance for People Living with HIV/AIDS in Seven Area Counties: PRNewswire - December 20, 2004; BOSTON, Dec. 20 /PRNewswire/ -- The AIDS Action Committee of Massachusetts, Inc. is administering a Utility Assistance Program for people living with HIV/AIDS in Suffolk, Middlesex, Plymouth, Norfolk, Bristol, Worcester and Essex Counties. The project is being funded by the Boston Public Health Commission (BPHC). Effec
U.S. FDA Approves New 500 mg Tablet Formulation of INVIRASE(R) -- New tablet reduces number of INVIRASE pills for HIV patients; approved after six-month FDA priority review --: PRNewswire - December 20, 2004; NUTLEY, N.J. -- Roche today announced U.S. Food and Drug Administration ( FDA ) approval of a new 500 mg film-coated tablet formulation of its HIV protease inhibitor INVIRASE(R) (saquinavir mesylate), designed for use in combination with a small dose of ritonavir and other anti-HIV drugs for the treatment of HIV infect
Celebrex, Vioxx Scandals Prompt AIDS Group to Call for Ban on Consumer Drug Advertising: AIDS Healthcare Foundation Says New Independent Panel Should Oversee All Drug Research: PRNewswire - December 17, 2004; What: MEDIA AVAILABILITY -- AHF Calls for Emergency Ban on Direct to Consumer Drug Advertising & Creation of a New Panel to Review Drug Research Who: Michael Weinstein, President, AIDS Healthcare Foundation Contact: Ged Kenslea, AHF Communications Director, 323.860.5225(w) 323.791.5526(m) LOS ANGELES, Dec.
Mymetics Receives NIH Approval to Advance HIV Vaccine Into Late Preclinical Studies: PRNewswire - December 17, 2004; NYON, Switzerland , Dec. 17 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) announced today that it has received approval from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to begin advanced preclinical testing of the Company s tri
Tides Foundation Receives $1 Million From the World Health Organization for Collaborative Fund for HIV Treatment Preparedness: PRNewswire - December 16, 2004; -- WHO Grant Supports HIV Treatment Advocacy and Education Efforts in Communities Around the World SAN FRANCISCO, Dec. 16 /PRNewswire/ -- Tides Foundation has been awarded a $1 million grant from the World Health Organization (WHO) in support of the Collaborative Fund for HIV Treatment Preparedness to support community
Secretary Thompson Announces PACHA Co-Chair: PRNewswire - December 16, 2004; WASHINGTON, Dec. 16 /PRNewswire/ -- HHS Secretary Tommy G. Thompson today announced Anita Smith as the co-chair of the Presidential Advisory Council on HIV/AIDS (PACHA). The PACHA provides the President and the Secretary with recommendations regarding programs and policies intended to anticipate and respond to the Worl
FIND and BD Combine International Efforts to Improve Rapid Tuberculosis Diagnosis for HIV-positive Patients in Developing Countries: PRNewswire - December 15, 2004; GENEVA, and FRANKLIN LAKES, N.J., Dec. 15 /PRNewswire-FirstCall/ -- FIND (Foundation for Innovative New Diagnostics) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced an international collaboration aimed at improving diagnosis of pulmonary tuberculosis (TB) in HIV-infected patients in developing countr
Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART: PRNewswire - December 15, 2004; MONTEGO BAY, Jamaica , Dec. 15 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD) demonstrated sustained viral suppression and safety over 120 weeks, according to data pres
You're Hired!!! Bid on Props and Memorabilia From 'The Apprentice' at www.Apprentice-auction.com December 16 - 29 to Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - December 14, 2004; -- Signed Items By Donald Trump, Show Contestants and More to Raise Funds for Lifesaving Pediatric Research SANTA MONICA, Calif., Dec. 14 /PRNewswire/ -- On Thursday, December 16, one lucky contestant on the NBC-TV phenomenon The Apprentice will receive the opportunity of a lifetime when Donald Trump utters the words w
US Needs Blue Ribbon Commission to Review All Drug Research Says AHF: Safety of AIDS Drug to Prevent Mother-to-Child Transmission of HIV Questioned: PRNewswire - December 13, 2004; -- As White House Prepared Launch of Global AIDS Program, NIH Officials Reportedly Kept Flawed Study Data From Administration. On Heels of Recent Scandals Involving the FDA and NIH, US Largest AIDS Group Says New Independent Panel Must Be Convened to Oversee All Drug Research What: MEDIA AVAILABILITY - Call for New Pan
Survivor: Vanuatu Props and Memorabilia Up for Bid on eBay December 12-26 to Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - December 13, 2004; -- Fans Are Encouraged to Visit http://www.Survivor-Auction.com and Out Last, Out Play and Out Bid All for a Great Cause SANTA MONICA, Calif., Dec. 13 /PRNewswire/ -- The warm waters of the South Pacific proved to be no vacation for the most unforgettable, quirky and controversial castaways the CBS-TV adventure series,
Panacos Pharmaceuticals Announces Initiation of Phase 2 Clinical Development of its HIV Drug Candidate, PA-457: PRNewswire - December 10, 2004; GAITHERSBURG, Md., Dec. 10 /PRNewswire/ -- Panacos Pharmaceuticals, Inc., today announced the initiation of a Phase 2a clinical trial of PA-457, the first in a new class of HIV drug candidates called Maturation Inhibitors. Institutional Review Board (IRB) and other approvals have been received and the study is now open
World Vision 'Gifts of Hope' Help Build a Better World for Children: More Than 120 Ways to Benefit the World's Children in the Name of Loved Ones: PRNewswire - December 9, 2004; SEATTLE, Dec. 9 /PRNewswire/ -- As harsh and perilous as many parts of the world are for impoverished children and families, there is hope. This hope arrives tangibly to hard-working people worldwide each year in the form of income -- producing animals, clean water, seeds and tools, and much more -- from the hearts of
MedMira Rapid HIV Test Ranked No. 1 in China: Accuracy of MiraWell(TM) Rapid HIV Test as Good as Traditional Tests: PRNewswire - December 9, 2004; HALIFAX, Dec. 9 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that its MiraWell(TM) Rapid HIV Test has been designated as the number one rapid HIV antibody test, according to results of the
Novel Antibiotic Shows Promise in Shortening Treatment Duration of Tuberculosis: PRNewswire - December 9, 2004; RARITAN, N.J., Dec. 9 /PRNewswire/ -- Scientists at Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) have identified a novel anti- tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection. Also, preliminary studies in healthy hum
MedMira Engages Distributor for Middle East: Rapid HIV Test to be Carried by Established Distributor: PRNewswire - December 7, 2004; HALIFAX, Dec. 7 /PRNewswire-FirstCall/ - MedMira Inc., ( MedMira ) (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has engaged the Prestige Group of Abu Dhabi, the medical device and pharmaceuticals division of the US $4.5 billion Al Jaber
China Can Avert Major AIDS Crisis and Beat TB Epidemic: But Drastic Scale-Up Necessary to Keep Ahead of Growing Pandemics: PRNewswire - December 6, 2004; BEIJING, Dec. 6 /Xinhua-PRNewswire/ -- In discussions with senior Chinese government officials, Richard Feachem, the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, praised China s recent response to its growing HIV/AIDS problem and its actions against tuberculosis. In China to discuss Gl
Ronald McDonald House Charities(R) (RMHC(R)) Marks World AIDS Day with Continued Support for Global Fight Against HIV/AIDS: PRNewswire - December 3, 2004; -- Grant to Elizabeth Glaser Pediatric AIDS Foundation Will Help Women and Children in Cameroon by Reducing Mother-to-Child Transmission of HIV OAK BROOK, Ill., Dec. 3 /PRNewswire/ -- Ronald McDonald House Charities today awarded a grant of US$300,000 (XAF 153,774,000 CFA franc) to the Elizabeth Glaser Pediatric AIDS F
Massachusetts Health Care Leaders Report State Government Lags Behind Changing Face Of AIDS: PRNewswire - December 3, 2004; BOSTON, Dec. 3 /PRNewswire/ -- In recognition of World AIDS Day, the Massachusetts Health Policy Forum (The Forum) convened state health care leaders on Wednesday to evaluate the progress made in combating AIDS in Massachusetts over the past 10 years. At the conference, the Forum released its report titled HIV/AIDS in
Healed of AIDS by Philip Savage: Catharsis Releases Astounding Test Results for Gay Businessman Who Has Won 10-Year Battle Against Incurable Immune Disease: PRNewswire - December 1, 2004; MONTGOMERY, Ala., Dec. 1 /PRNewswire/ -- Catharsis, a California not-for-profit corporation releases astounding HIV viral test results for Buz Crump, a 50-year-old gay businessman diagnosed as having HIV/AIDS for 10 years. Despite arsenals of medications, Crump suffered numerous infections, while his HIV viral load (a
World AIDS Day Chosen to Launch HIV/AIDS Radio Network, First All HIV/AIDS 'On Demand' Radio Network to Tackle AIDS: PRNewswire - December 1, 2004; SAN FRANCISCO, Dec. 1 /PRNewswire/ -- Aldagon Resources and the Affiliate Nanocasting Network (ANN) announced today the launch of the HIV/AIDS Radio Network -- the first on demand radio network dedicated to airing the voices of HIV and AIDS from around the world. The Network s pilot program, HIV and Me Talk Radio, pre
Roche Employees Walked 'Around the World' to Commemorate World AIDS Day in Second Annual Global Employee AIDS Walk Benefiting Charities Worldwide: PRNewswire - December 1, 2004; -- Six U.S. Roche sites join forces in supporting global fight against HIV/AIDS NUTLEY, N.J., Dec. 1 /PRNewswire/ -- More than 8,000 Roche employees from 33 countries and 60 sites collectively walked nearly 25,000 miles to raise funds today for local and international AIDS organizations. Funds raised by employee sponso
IPM Hails CAD $15 Million to Support Microbicide Research and Development to Protect Women Against HIV: PRNewswire - December 1, 2004; -- Canadian International Development Agency (CIDA) Makes Commitment on World AIDS Day - 2004 Theme is Women, Girls, HIV and AIDS SILVER SPRING, Md., Dec. 1 /PRNewswire/ -- The International Partnership for Microbicides (IPM) applauds the Canadian International Development Agency (CIDA) today for contributing CAD$ 15 m
Calypte Biomedical Initiates China Clinical Trials of Rapid Test Platform: PRNewswire - December 1, 2004; PLEASANTON, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has initiated a clinical trial program of its rapid HIV-1/2 test platform and HIV-1 Western blot supplemental tests in The Peoples Republic of China (China). The trial will evaluate the sensitivity an
New Program Offers Immediate Access to FUZEON(R) for Patients In Expanded Access Programs of Investigational HIV Therapies: PRNewswire - December 1, 2004; -- FUZEON Accelerated Simultaneous Access Program (ASAP) Addresses Critical Needs for Growing Number of Treatment-Experienced Patients NUTLEY, N.J. and DURHAM, N.C., Dec. 1 /PRNewswire/ -- To address the needs of treatment experienced patients living with HIV disease, Roche and Trimeris are launching the FUZEON Acceler
Boehringer Ingelheim Announces U.S. Expanded Access Program for Anti-HIV Drug Tipranavir: PRNewswire - November 30, 2004; -- Program Will Provide Drug to HIV-Infected Patients with Limited Treatment Options RIDGEFIELD, Conn., Nov. 30 /PRNewswire-FirstCall/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the opening of the tipranavir Expanded Access Program (EAP) in the U.S., following the recent review of the protocol (1) by
AIDS Healthcare Foundation Joins With The China Foundation in New Global AIDS Partnership in Shanxi Province, China: PRNewswire - November 30, 2004; -- HIV Testing, Treatment and Training Efforts Will Target Yuncheng City Residents in Province Where Blood Selling of Villagers Led to Widespread HIV Infections -- Partners Will Host Receptions in Washington, DC, Nov. 30th and Shanxi Province, China, on December 1st WASHINGTON, Nov. 30 /PRNewswire/ -- The China Foundat
Bristol-Myers Squibb Invites Yahoo!'s Global Audience to Shine a Light on the HIV/AIDS Crisis on World AIDS Day: PRNewswire - November 30, 2004; -- Light to Unite Campaign Helps Raise HIV/AIDS Awareness on Nine Yahoo! Front Pages NEW YORK, Nov. 30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) is working with Yahoo! to raise awareness of the global HIV/AIDS crisis through the Light to Unite initiative on World AIDS Day. The Company will spo
Statement by Tommy G. Thompson, Secretary of Health and Human Services Regarding World AIDS Day 2004, December 1, 2004: PRNewswire - November 30, 2004; WASHINGTON, Nov. 30 /PRNewswire/ -- The following is a statement by Tommy G. Thompson, Secretary of Health and Human Services regarding World AIDS Day 2004, December 1, 2004: World AIDS Day is an important opportunity to remember those lost to AIDS. Just as importantly, it is an opportunity to raise awareness of the gl
Women Living With HIV Break Their Silence on HIV and Me Talk Radio, the First 'On Demand' Radio Program Dedicated to HIV/AIDS: PRNewswire - November 30, 2004; SAN FRANCISCO, Nov. 30 /PRNewswire/ -- Two women who have been living with HIV/AIDS speak candidly on the HIV/AIDS Radio Network about how their lives have been affected by this disease. These guests shatter many of the misconceptions people have about HIV and AIDS being a disease that affects gay men and intravenous d
113 Abstracts on Recent Clinical Data for Thalomid(R), Revlimid(TM), Actimid(TM) and Alkeran(R) to be Presented at the American Society of Hematology 46th Annual Meeting: PRNewswire - November 30, 2004; -- Forty-Nine Abstracts on Thalidomide in Single and Combination Therapies in Newly Diagnosed Multiple Myeloma and Other Hematological Cancers WARREN, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators from leading cancer research centers will present
Update: CBS Bans Anti-Syphilis Ad: AHF Fears 'Chilling Effect of 'Moral Values' on Safer Sex Education'; Will Seek FCC Ruling: PRNewswire - November 30, 2004; -- Rejected Stop the Sores TV Spot for Syphilis Prevention Campaign has Already Run on Area Cable Outlets Such as CNN, Bravo and A&E; Campaign Targeting Gay & Bisexual Men in L.A. is Backed by Community Coalition Including AHF & LA County Health Dept. s Office of STD Program What: PRESS CONFERENCE-LA area B
Lil' Kim and Rosie Perez to be Special Guest Hosts at Move Against AIDS: Return of the Dance-a-thon: PRNewswire - November 29, 2004; NEW YORK, Nov. 29 /PRNewswire/ -- Hip-Hop icon Lil Kim and actress Rosie Perez, currently on Broadway in the smash hit Reckless, have signed on as special guest hosts of Move Against AIDS: Return of the Dance-a-thon, on December 11, 2004, at the Jacob Javits Convention Center in Manhattan. Lil Kim and Rosie Perez join
Viral Genetics Announces Publication of Study on Effects of VGV-1 in Antiretroviral Non-Responding HIV Infections: PRNewswire - November 29, 2004; -- Treatment of VGV-1 Given Over Two Months in Subjects Failing Antiretroviral Therapy -- 5/10 Patients Reach Undetectable HIV Virus Levels by Three Months -- One Log Drop in HIV Virus Levels Observed by Six Months AZUSA, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Viral Genetics (OTC Bulletin Board: VRAL), a drug discov
Lipid Sciences' Viral Advisory Board Reviews Viral Immunotherapy Research Program: Positive Preliminary Results Seen in Non-human Primate Study: PRNewswire - November 29, 2004; PLEASANTON, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) today announced positive new data related to the Company s Viral Immunotherapy program was reviewed at a meeting of the Lipid Sciences Viral Advisory Board held last month. In December 2003, the Company announced the completion of
Mobilizing Business Women Leaders in the Fight Against HIV/AIDS: PRNewswire - November 29, 2004; CHICAGO, Nov. 29 /PRNewswire/ -- Millions of girls are dying on our watch. With this compelling charge, Mary Robinson, former United Nations High Commissioner for Human Rights and president of Ireland , opened the inaugural meeting of the Steering Committee of the Business Women s Initiative Against HIV/AIDS (BWI).
Kenneth Cole to Become amfAR Chairman: amfAR Honors Outstanding Research Focused on Women and HIV/AIDS at World AIDS Day Luncheon: PRNewswire - November 29, 2004; NEW YORK, Nov. 29 /PRNewswire/ -- Kenneth Cole, Chairman-designate of the American Foundation for AIDS Research (amfAR) will join amfAR in honoring outstanding contributions to the field of women and HIV/AIDS at a luncheon tomorrow at the Time, Inc. Conference Center, co-sponsored by the Mailman School of Public Health
M.A.C Aids Fund Raises $40 Million in Ten Years for People Living With HIV/AIDS: PRNewswire - November 29, 2004; -- In 2004 Missy Elliott, Christina Aguilera, Chloe Sevigny, Boy George, Linda Evangelista Helped Raise $8 Million -- M.A.C President and M.A.C AIDS Fund Chairman John Demsey to speak at The International Center for Research on Women (ICRW) Conference In Washington, D.C. On World AIDS Day NEW YORK, Nov. 29 /PRNewswire/
India.Arie Explores the Worldwide Struggle Against HIV/AIDS in 'VH1 NEWS PRESENTS: Battling The Global AIDS Epidemic': PRNewswire - November 29, 2004; -- A Special Highlighting VH1 s Partnership With the Global Fund to Fight AIDS, Tuberculosis and Malaria NEW YORK, Nov. 29 /PRNewswire/ -- AIDS. The world s worst ever health crisis. As part of its continuing public affairs initiative VH1, invited India .Arie to come up close -- real close -- by spending time with thos
Nick News Talks With Kids Living With AIDS in a Special to Air on World AIDS Day: PRNewswire - November 29, 2004; -- Nick News Special Edition: Living With AIDS: A Story of Three Kids to Air Dec. 1, 2004, at 8:30 p.m. (ET/PT) on Nickelodeon NEW YORK, Nov. 29 /PRNewswire/ -- More than 14,000 kids in the United States are infected with the HIV virus, and more than 90 percent of the kids infected were born with the disease. For a ki
World AIDS Day: Americans Walking for Orphans: PRNewswire - November 29, 2004; -- From Appalachia to China s Great Wall, People Matching Steps to Number of Children Affected by Pandemic SEATTLE, Nov. 29 /PRNewswire/ -- On World AIDS Day (December 1), as on every day, 6,000 children will lose their parents. This year, several hundred Americans will take action to help these children with both thei
Bayer and Tsinghua University Inaugurate Public Health and HIV/AIDS Media Studies Program: PRNewswire - November 22, 2004; -- Improvement of Health Through Communications -- a National Platform for Healthcare Reporting BEIJING, Nov. 22 /Xinhua-PRNewswire/ -- Bayer China and Tsinghua University have inaugurated a groundbreaking new initiative today, the Tsinghua -- Bayer Public Health and HIV/AIDS Media Studies Program, designed to play a
A Skate for Remembrance and Hope - Blades Against AIDS 2, A World AIDS Day Benefit for Body Positive: PRNewswire - November 22, 2004; NEW YORK, Nov. 22 /PRNewswire/ -- Join Body Positive at its second annual World AIDS Day fundraiser Blades Against AIDS 2, co-produced by the New York City Gay Hockey Association, 64events.com and Out of Bounds. This event takes place on Wednesday, December 1 from 8pm to Midnight at the Sky Rink at Chelsea Piers, Pier
Remarks by President Bush at CEO Summit Closing Session: PRNewswire - November 20, 2004; WASHINGTON, Nov. 20 /PRNewswire/ -- The following is a transcript of remarks by President Bush at CEO Summit closing session: Casa Piedra Santiago, Chile 4:47 P.M. (Local) PRESIDENT BUSH: Thank you very much. Siente se. Gracias. Thank you for the warm welcome. It is such an honor to be in Chile. Whoever is responsible
Bentley Pharmaceuticals Reports Auxilium's Announcement of Study Results Demonstrating That Testim(R) Delivered Using Bentley's CPE-215 Technology is Effective in Treating HIV-Positive Hypogonadal Men - Testim(R) Treated Men Experienced Sexual Function Improvement versus AndroGel(R) -: PRNewswire - November 19, 2004; EXETER, N.H., Nov. 19 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company focused on advanced drug delivery technologies, which also manufactures and markets a growing branded and generic product line in Europe, today announced that Auxilium Pharmaceuticals (Nasdaq: A
AHF Says 'FDA Fiasco' Raises Questions About AIDS Drug Approvals for Developing World: PRNewswire - November 19, 2004; -- Current Crisis Over Merck s Drug, Vioxx, Raise Questions About US Agency s Role in Approval of Generic AIDS Drugs for Use in Africa and the Developing World; FDA s Approval, Then Recall of Arthritis Medication Dispels Drug Industry Spin That Branded Equals Safe LOS ANGELES, Nov. 19 /PRNewswire/ -- AIDS Healthcare Fo
HHS Awards $10.4 Million to Fight AIDS On Three Continents: PRNewswire - November 18, 2004; WASHINGTON, Nov. 18 /PRNewswire/ -- HHS Secretary Tommy G. Thompson today announced four new grants totaling $10.4 million to provide support for HIV/AIDS research in Peru , Thailand , Cambodia and Russia , four nations
Boehringer Ingelheim Announces 24-Week Interim Results From Second Phase 3 Pivotal Study of Tipranavir: PRNewswire - November 18, 2004; GLASGOW, Scotland, Nov. 18 /PRNewswire/ -- New data from a pivotal Phase 3 study (RESIST-2) show that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed
Updated Federal Guidelines Recommend RETROVIR + EPIVIR as Part of First-Line Therapy in ART Regimens: Recommended Drugs Available as COMBIVIR Fixed Dose Tablet: PRNewswire - November 18, 2004; RESEARCH TRIANGLE PARK, N.C., Nov. 18 /PRNewswire/ -- Revised federal guidelines recommend RETROVIR(R) (zidovudine, ZDV) and EPIVIR(R) (lamivudine, 3TC ) as one of the preferred dual nucleoside reverse transcriptase inhibitor (NRTI) backbones used as part of initial HIV combination therapy. RETROVIR and EPIVIR are ava
Auxilium Announces Study Results Demonstrating Testim(R)1% Effective in Treating HIV-Positive Hypogonadal Men: PRNewswire - November 17, 2004; -- Testim-Treated Men Experienced Sexual Function Improvement versus AndroGel(R) NORRISTOWN, Pa., Nov. 17 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals (Nasdaq: AUXL), a specialty pharmaceutical company that develops and markets products for urologic and sexual health, today announced top line study results compar
Study Reveals Widespread Use of Antacids and Other Heartburn Medications Among HIV Patients -- pH-altering Characteristics of these Drugs May Have Implications for the Clinical Management of HIV Patients: PRNewswire - November 17, 2004; GLASGOW, Scotland, Nov. 17 /PRNewswire/ -- A survey conducted among HIV- positive patients has uncovered frequent use of prescription and over-the- counter (OTC) medications for the treatment of heartburn, gastroesophageal reflux disease (GERD) and ulcers. Because these medications increase the pH level in the stomach,
The Immune Response Corporation Presents Preliminary Analysis of REMUNE Phase II Trial in HIV Positive, Drug Naive Patients - Data Show Positive Trends in Key Immune Response Markers at 28 Weeks -: PRNewswire - November 17, 2004; CARLSBAD, Calif., Nov. 17 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, presented preliminary data this week from an ongoing Italian Phase II study of REMUNE(R) treatment i
Public Interest Watch Condemns Doctors Without Borders for Creating New HIV Strains: Public Interest Watch Concerned French NGOs Use of Substandard Generics Could Lose Fight Against AIDS: PRNewswire - November 16, 2004; LOS ANGELES, Nov. 16 /PRNewswire/ -- Public Interest Watch (http://www.publicinterestwatch.org) today condemned French charity Doctors Without Borders (MSF) for its gross negligence in putting substandard AIDS drugs on the market in 27 countries, with the very real possibility of having caused new strains of drug-resis
VH1 Commemorates World AIDS Day on Wednesday, December 1 With Original Programming and PSAs That Re-Ignite Awareness About This Global Pandemic: PRNewswire - November 16, 2004; NEW YORK, Nov. 16 /PRNewswire/ -- As part of VH1 s ongoing public affairs initiative to generate awareness about the AIDS pandemic, the network will air the award-winning VH1 News Presents: AIDS: A Pop Culture History as well as original public service announcements (PSAs) and a VH1 News package throughout World AIDS D
United States Health and Human Services Secretary Tommy G. Thompson Applauds Effective Public-Private Partnership Advancing HIV/AIDS Care in Tanzania: PRNewswire - November 16, 2004; DAR ES SALAAM, Tanzania , Nov. 16 /PRNewswire-FirstCall/ -- Today Abbott welcomed United States Secretary of Health and Human Services Tommy G. Thompson to Muhimbili National Hospital in Dar es Salaam where the Secretary saw first-hand a view of the comprehensive health care management and infrastructure improvements t
Waxman and Kennedy Push for UN's Defective AIDS Drugs May Leave the Taxpayer Liable to Tort Claims: PRNewswire - November 15, 2004; FAIRFAX, Va., Nov. 15 /PRNewswire/ -- After an Indian company recalled all of its generic AIDS drugs from the market this week, there are considerable liability issues in play and the members of Congress who aggressively touted the dangerous and unproven medicines may leave American taxpayers footing the bill. India s
ESSENCE Magazine Makes 100% Commitment to the Fight Against HIV/AIDS Joins Forces With The Black Aids Institute In The Our People. Our Problem. Our Solution. Awareness Campaign: PRNewswire - November 15, 2004; -- Actress and Comedienne Mo Nique Will Serve As Campaign Spokesperson NEW YORK, Nov. 15 /PRNewswire/ -- ESSENCE will observe the holiday season with a special HIV/AIDS awareness campaign called, Our People. Our Problem. Our Solution. The preeminent magazine for African-American women has teamed up with The Black AIDS
KNOW HIV/AIDS Teams Up With Hip-Hop Sensation Common to Promote HIV Testing: PRNewswire - November 15, 2004; -- Viacom and Kaiser Family Foundation s Initiative Supports World AIDS Day Through HIV/AIDS-Related Television Programming, PSAs, News Specials and Events NEW YORK, Nov. 15 /PRNewswire/ -- Viacom Inc. and the Henry J. Kaiser Family Foundation today announced the launch of a new set of public service advertisements (PS
GlaxoSmithKline Awards $250,000 in Research Grants to Three Scientists For Their Research to Develop Breakthrough Drug Therapies for HIV/AIDS: PRNewswire - November 15, 2004; RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire/ -- The 2004 GlaxoSmithKline (GSK) Drug Discovery and Development Research Grants have recently been awarded to three scientists working on novel approaches to combat HIV, the virus that causes AIDS. The recipients, who will share equally in a total of $250,000 in grant
Nick News Talks With Kids Living With AIDS in a Special to Air on World AIDS Day: PRNewswire - November 11, 2004; Nick News Special Edition: Living With AIDS: A Story of Three Kids to Air Dec. 1, 2004, at 8:30 P.M. (ET/PT) on Nickelodeon NEW YORK, Nov. 11 /PRNewswire/ -- More than 14,000 kids in the United States are infected with the HIV virus, and more than 90 percent of the kids infected were born with the disease. For a kid g
Pharmasset Initiates Racivir(R) Phase II HIV Study: PRNewswire - November 10, 2004; ATLANTA, Nov. 10 /PRNewswire/ -- Pharmasset, Inc. has initiated a Phase II clinical study to assess the safety, tolerability, and antiviral effect of substituting Racivir (RCV) for Epivir (R) (lamivudine, 3TC ) in treatment- experienced HIV-infected individuals.
AHF Commends Sheriff's Department for Successful HIV Prevention and Testing Project in LA County Jails: PRNewswire - November 10, 2004; -- The LA County Board of Supervisors on Tuesday Recognized the Sheriff s Department for Its Successful HIV Prevention and Testing Program in LA County Jails and Correction Facilities. AIDS Healthcare Foundation and Other County HIV Prevention and Testing Programs Join in This Success. LOS ANGELES, Nov. 10 /PRNewswire/
Trinity Biotech Receives CLIA Waiver for Uni-Gold(TM) Recombigen(R) HIV Test: PRNewswire - November 10, 2004; DUBLIN, Ireland , November 10 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) today announced that the US Food & Drug Administration ( FDA ) has approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for the Uni-Gold(TM) Recombigen(R) HIV test.
Fourth Annual Black AIDS Institute Gala Celebration Honors African-Americans in the Fight Against AIDS: Star-Studded Event Scheduled to Take Place in Hollywood Nov. 12: PRNewswire - November 10, 2004; LOS ANGELES, Nov. 10 /PRNewswire/ -- On November 12th, the Black AIDS Institute will unveil the portraits of the 2004 Heroes in the Struggle at the fourth annual Gala Reception and Awards Ceremony at the Directors Guild of America in Hollywood. Heroes in the Struggle is a photographic tribute to people of African desce
Medical Services Moves VScan Test Kits Into Russia: PRNewswire - November 9, 2004; EDMONTON, Alberta, Nov. 9 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that it has signed an agreement with a distributor in Russia to distribute the VScan test kits in Russia and surrounding countries. The Distributor already has a well defined distribution
TNX-355 Among HIV Therapies Highlighted at International Meeting of the Institute of Human Virology: PRNewswire - November 9, 2004; HOUSTON, Nov. 9 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) Medical Director Dr. Stanley Lewis recently presented findings from the Phase I clinical trial of TNX-355 for the treatment of human immunodeficiency virus (HIV) at the 2004 International Meeting of the Institute of Human Virology (IHV) in Baltimore,
A.L.B.R.C. Set to Oppose Continued Domination of $18 Billion Domestic HIV/AIDS Relief Funds by 'Gay Power Elite': PRNewswire - November 9, 2004; -- With Bush Receiving 16% of the Black Vote in Ohio; A.L.B.R.C. Calls for Significant Changes in the Ryan White Care Act and Other AIDS Relief Programs DALLAS, Nov. 9 /PRNewswire/ -- Stating that the A.L.B.R.C. shares the general opinion of most political pundits: marriage for gays probably cost the Democrats the elec
Panacos Pharmaceuticals Amends Merger Agreement with V.I. Technologies - Reports Accelerated Development of PA-457, Lead HIV Drug Candidate: PRNewswire - November 8, 2004; GAITHERSBURG, Md., Nov. 8 /PRNewswire/ -- Panacos Pharmaceuticals, Inc., a privately-held company developing novel therapeutics for the treatment of HIV and other major human viral diseases, today announced that it has amended the terms of its merger agreement with Watertown, MA-based V.I. Technologies, Inc. (Nasdaq: V
Research and Markets: Investigate Today's HIV Competitive Landscape: PRNewswire - November 4, 2004; DUBLIN, Ireland , Nov. 4 /PRNewswire/ -- The world-wide HIV competitive landscape, involves more than 110 drug developing companies and this report has reviewed its last ten years, 1994-2004, of business interactions, ranging from licensing deals to M&As. From 66 carefully selected business interactions, we have cr
AHF Says California Studies on HIV Rates Among Mexican Migrant Workers Require Targeted Prevention & Treatment Efforts to Better Contain Epidemic: PRNewswire - November 2, 2004; -- Two Studies in Fresno and San Diego Counties Show HIV Incidence Among Mexican Migrant Workers at Three Times the Level of the General Population in U.S. and Mexico LOS ANGELES, Nov. 2 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS organization, which operates free AIDS treatment clinics in the
Human Genome Sciences Characterizes Panel of Novel Human Monoclonal Antibodies That Specifically Antagonize the CCR5 Receptor and Block HIV-1 Entry: PRNewswire - November 2, 2004; -- Candidate Antibody Selected for Further Evaluation of Anti-HIV/AIDS Properties -- Data Presented at 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has identified and chara
Chinese Blood Centres To Use MedMira's Rapid HIV Tests: Increases Presence in China Public Health Initiative: PRNewswire - November 2, 2004; HALIFAX, Nov. 2 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that it has shipped 100,000 MiraWell(TM) Rapid HIV Tests to one of its distributors in the People s Republic of
Whole Foods Market(R) to Raise Funds for the Boston Living Center to Provide Meals for People Living With HIV/AIDS: PRNewswire - November 1, 2004; BOSTON, Nov. 1 /PRNewswire/ -- This month, shoppers at the 13 greater Boston-area locations of Whole Foods Market (formerly Bread and Circus) can provide meals to people living with HIV who might otherwise go hungry. During the month-long promotion, people can Buy a Meal for Someone Living with HIV/AIDS by making a tax
Land O'Lakes Partners With Hoops4Africa to Combat Africa's HIV/AIDS Pandemic: PRNewswire - November 1, 2004; ARDEN HILLS, Minn., Nov. 1 /PRNewswire/ -- At a reception last Thursday evening in Washington, DC, Land O Lakes, Inc., a leading U.S. food and agricultural cooperative, and top NBA and WNBA players formally launched a unique partnership of combining their assets and expertise in the fight against the HIV/AIDS pandemic
THE LION SINGS TONIGHT: Company Members of Disney's The Lion King to Perform an Evening of Song and Dance to Benefit AIDS Action: PRNewswire - November 1, 2004; BOSTON, Nov. 1 /PRNewswire/ -- On Monday, Nov. 15th only, members of the cast of Disney s The Lion King will donate their time and talent to shake loose and sing some of their favorite songs from the world of cabaret, pop, rock and R&B, at a special performance called The Lion Sings Tonight as a benefit for AIDS Ac
Longest Study of Kaletra(R) (Lopinavir/Ritonavir) Based Regimen Demonstrated Favorable Resistance Profile for Patients Through Six Years of Initial HIV Therapy: PRNewswire - November 1, 2004; WASHINGTON, Nov. 1 /PRNewswire/ -- Study data presented showed no primary protease inhibitor (PI) resistance was reported in anti-retroviral-naive patients taking a Kaletra (R) ( lopinavir / ritonavir )-based regimen through six years (300 weeks) of
City HIV/AIDS Expert, Dr. Marjorie Hill, Joins Gay Men's Health Crisis: PRNewswire - November 1, 2004; NEW YORK, Nov. 1 /PRNewswire/ -- Gay Men s Health Crisis (GMHC) today announced that Marjorie J. Hill, Ph.D., a prominent leader in the HIV/AIDS community, will join the agency to expand its work directed at women and families in the AIDS epidemic. Prior to joining GMHC, Dr. Hill was Assistant Commissioner for HIV/AIDS
Boehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study: PRNewswire - November 1, 2004; WASHINGTON -- New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs)
Clinical Study Results Build Case for Expanded Use of FUZEON(R) -- Data, Together with New HIV Treatment Guidelines, Support Use in Broad Range of Treatment-Experienced Patients: PRNewswire - October 31, 2004; WASHINGTON, Oct. 31 /PRNewswire-FirstCall/ -- Earlier use of FUZEON(R) ( enfuvirtide ) in treatment-experienced HIV patients results in better treatment outcomes and preserves future drug options, according to new data presented today at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
GlaxoSmithKline Perspective on Data Involving Combivir Presented at ICAAC: PRNewswire - October 31, 2004; WASHINGTON, Oct. 31 /PRNewswire/ -- A significant number of abstracts that include Combivir (R) (lamivudine 150 mg and zidovudine 300 mg) Tablets are being presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C. Among these is one abstract with data from a 24-week ana
New Information About TRIZIVIR Presented at ICAAC: PRNewswire - October 31, 2004; At a Glance -- The quad NRTI regimen of TRIZIVIR + tenofovir shows efficacy in treatment-naive patients; may preserve future treatment options. -- Patients who achieved viral suppression on an initial ART regimen retain viral suppression when switched to a simplified regimen of TRIZIVIR alone, or COMBIVIR +
Evidence That HIV Protease Inhibitor, LEXIVA Plus Ritonavir (RTV) May Replace AGENERASE + RTV Without Pharmacokinetic Impact Presented at ICAAC: PRNewswire - October 30, 2004; At a Glance According to preliminary data presented at ICAAC: -- Ritonavir (RTV) increased plasma PK parameters to a similar extent when co-administered with LEXIVA or APV. -- LEXIVA is the first PI with flexible dosing and no food or fluid restrictions, which may help simplify ART regimens for some patients.
Increases in HDL Cholesterol Observed in Patients Taking LEXIVA, According to New Data Presented at ICAAC: PRNewswire - October 30, 2004; According to 48-week data presented at ICAAC: -- Levels of HDL-C, were increased in patients taking LEXIVA who had low HDL-C at baseline. -- There were minimal changes in TC/HDL-C ratios. Additional results seen at 120 weeks were presented last week at the International Workshop on Adverse Drug Reactions and Lipodystro
ViroLogic Announces Presentations at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): PRNewswire - October 29, 2004; SOUTH SAN FRANCISCO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that Christos J. Petropoulos, Ph.D., Vice President of Research and Development at ViroLogic, will be making an oral presentation on Viral Fitness at the invitation of the organizing committee of the 44th Inter
Docs Without Drugs: APUA Report Reveals Urgency of Drug Resistance Worldwide - Describes impending loss of front-line antimicrobials, a major public health threat: PRNewswire - October 29, 2004; WASHINGTON -- A new report released at a meeting of the American Society for Microbiology (ASM), describes the ominous presence of disease-causing microorganisms resistant to today s front- line drugs. Shadow Epidemic: The Growing Menace of Drug Resistance presents up-to-date findings from major groups tracking resista
MedMira Donates Rapid HIV Tests In China: Supports National Government HIV Prevention Strategy: PRNewswire - October 27, 2004; HALIFAX, Oct. 27 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that it has made donations of 25,000 MiraWell(TM) Rapid HIV Tests to two organizations in the People s Republic of
Pediatric HIV/AIDS Medical Centers to be Built in African Nations of Lesotho and Swaziland: Funding Provided by Bristol-Myers Squibb's SECURE THE FUTURE(R) Program: PRNewswire - October 27, 2004; JOHANNESBURG, South Africa , Oct. 27 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY), New York; Baylor College of Medicine, Houston, Texas; and the governments of Lesotho and Swaziland announced that medical centers focused on caring for children with HIV/AIDS
Condomania(R) Awards Over 30,000 'Madonna Condoms' to Nonprofits: PRNewswire - October 27, 2004; -- Douglas County AIDS Project and Planned Parenthood Are the Big Winners in Condomania s Madonna Condom Giveaway LOS ANGELES, Oct. 27 /PRNewswire/ -- Condomania (http://www.condomania.com), America s First Condom Store, announced today the winners of its Madonna Condom Giveaway. Condomania produced the contest to enco
BET's Rap-It-Up Heads to Newark for Celebrity Health Forum on November 6: Campaign Educates Young Adults About Safe Sex Practices; Promotes HIV/AIDS Awareness: PRNewswire - October 26, 2004; WASHINGTON, Oct. 26 /PRNewswire/ -- BET s Rap-It-Up, the cable network s national HIV/AIDS public awareness initiative, comes to the city of Newark, New Jersey to host a health forum in partnership with the University of Medicine/Dentistry of New Jersey (UMDNJ). The purpose of the health forum is to offer a platform fo
AHF Lauds Schwarzenegger's Work on AIDS Issues During First Year: PRNewswire - October 26, 2004; -- The Nation s Largest AIDS Organization Gives Schwarzenegger a Good Grade for His Work on AIDS Issues LOS ANGELES, Oct. 26 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US, which treats nearly 6,000 Californians living with HIV, applauds the efforts of Governor Schwarzenegger,
RxAmerica to Team With ADAP to Help HIV-Positive Utahns: PRNewswire - October 26, 2004; SALT LAKE CITY, Oct. 26 /PRNewswire/ -- The AIDS Drug Assistance Program (ADAP) of Utah announced it has chosen RxAmerica to manage its prescription benefit services. The HIV Treatment & Care Program is a federally funded drug assistance program, administered by the Utah Department of Health. The group accepted a m
Dynamics Research Corporation Wins $4.8 Million Contract to Support the Navy's HIV Management System: PRNewswire - October 26, 2004; -- Contract Leverages Extensive Military Medical IT Experience from Recent Acquisition of Impact Innovations ANDOVER, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Dynamics Research Corporation (Nasdaq: DRCO) announced today that a $4.8 million contract to support the National Navy Medical Center s Navy Central HIV Program
AIDS Organizations Warn State that Voter Challenges Will Result in Voter Inaccessibility: PRNewswire - October 26, 2004; -- Election Day Challenges May Cause Long Waits and Discourage Eligible Voters CLEVELAND, Oct. 26 /PRNewswire/ -- Today the AIDS Taskforce of Greater Cleveland, with support from a national coalition of AIDS organizations, demanded that elections officials provide full and equal access to people living with disabilitie
Theratechnologies to present results from its HIV-associated lipodystrophy Phase II study on ThGRF at scientific conferences in the U.S. and Italy: PRNewswire - October 25, 2004; MONTREAL, Oct. 25 /PRNewswire-FirstCall/ - Theratechnologies (TSX :TH) is pleased to announce that the results of its Phase II clinical trial on ThGRF in HIV- related lipodystrophy will be the subject of oral presentations by Dr. Steven Grinspoon, Lead Investigator in the United States , and by Dr. Julian Falutz, Lead
Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir: Priority Review Requested for Investigational Anti-HIV Agent: PRNewswire - October 25, 2004; RIDGEFIELD, Conn., Oct. 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for tipranavir. The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review o
Theratechnologies to present results from its HIV-associated lipodystrophy Phase II study on ThGRF at scientific conferences in the U.S. and Italy: PRNewswire - October 25, 2004; MONTREAL, Oct. 25 /PRNewswire-FirstCall/ -- Theratechnologies (TSX :TH) is pleased to announce that the results of its Phase II clinical trial on ThGRF in HIV- related lipodystrophy will be the subject of oral presentations by Dr. Steven Grinspoon, Lead Investigator in the United States , and by Dr. Julian Falutz, Lead
Calypte Biomedical to Begin Shipping HIV-1 Incidence Test: PRNewswire - October 25, 2004; PLEASANTON, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (AMEX:HIV) today announced that it will begin shipping its HIV-1 BED Incidence EIA test (Incidence Test) this week. The first shipment is destined for South Africa , and the Company currently has initial orders for approximately 12,000
Yes on Proposition 71 Launches Statewide Ad Featuring Christopher Reeve: PRNewswire - October 22, 2004; LOS ANGELES, Oct. 22 /PRNewswire/ -- Proponents of Yes on Proposition 71, the California Stem Cell Research and Cures Initiative, today announced the launch of a new television ad featuring Christopher Reeve that calls on voters to support the initiative. The 30-second television ad features actor/patient advocate Chri
THAT '70S SHOW and QUEER AS FOLK Among Winners at 20th SHINE Awards: PRNewswire - October 22, 2004; HBO Films Picks Up Special Honors; Laura Innes, Michael Beach, Debi Mazar, Callum Blue and Lupe Ontiveros Among Presenters at Fun-Filled Event; Hosted by Writer/Comedienne Julie Brown LOS ANGELES, Oct. 22 /PRNewswire/ -- Whether highlighting classic scenarios of parents having The Talk or a young person s coming out o
Health Canada Approves New MedMira Rapid HIV Test Achieves Second North American Regulatory Success: PRNewswire - October 21, 2004; HALIFAX, Oct. 21 /PRNewswire-FirstCall/ -- MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics for infectious diseases, announced today that it has received approval from Health Canada to market and sell its enhanced MedMira(TM) Rapid HIV Test for detection of
'Open Access' Medical Journal Provides New Model for Publishing Original, Peer-Reviewed Research: PLoS MEDICINE Launched on Internet This Week: PRNewswire - October 20, 2004; -- Free Online Journal Answers Call of Congress, NIH, Nobel Laureates for Increased Access to Biomedical Research SAN FRANCISCO, Oct. 20 /PRNewswire/ -- A new general medical journal launched this week with a non-traditional publishing model is the latest top- tier venue for publishing important, peer-reviewed biomedic
Health Secretary Announces $1 Million Grant for HIV Prevention: Philadelphia HIV/AIDS Rates 3 Times Higher Than State Average: PRNewswire - October 19, 2004; HARRISBURG, Pa., Oct. 19 /PRNewswire/ -- Health Secretary Dr. Calvin B. Johnson today joined Senator Vincent Hughes to announce $1 million for HIV prevention and education for minority youth in Philadelphia County. By targeting funding for proven HIV prevention services to the county with the highest HIV prevalence in
U.S. FDA Grants Traditional Approval for FUZEON(R), First and Only Fusion Inhibitor for the Treatment of HIV: PRNewswire - October 15, 2004; -- Designation Follows March 2003 Accelerated Approval and Further Confirms Safety and Efficacy at 48 Weeks NUTLEY, N.J. and DURHAM, N.C., Oct. 15 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that the U.S. Food and Drug Administration ( FDA ) has granted traditional approval to FUZE
Xilinx Rallies for the Walk for AIDS Silicon Valley: Company's Commitment to Silicon Valley AIDS Coalition Spans 13 Years: PRNewswire - October 13, 2004; SAN JOSE, Calif., Oct. 13 /PRNewswire/ -- As the sole Red Ribbon sponsor for the Walk for AIDS Silicon Valley, Xilinx, Inc. (Nasdaq: XLNX), today announced the company expects more than 300 walkers affiliated with Xilinx will participate in the 15th annual Walk for AIDS Silicon Valley, Sunday, October 17, 2004 at 9:00
Los Angeles Steps Up Support for 2004 AIDS Walk Marking 20th Year of the World's First AIDS Walk: PRNewswire - October 13, 2004; -- APLA Commemorates Inaugural Event, Honors AIDS Walk Founder LOS ANGELES, Oct. 13 /PRNewswire/ -- On Sunday, October 17, more than 25,000 people are expected to take to the streets for the 20th annual AIDS Walk Los Angeles, which benefits AIDS Project Los Angeles and other local AIDS organizations. AIDS Walk Los Ange
The United Nations Association San Diego Chapter Honors QUALCOMM Incorporated for Its Philanthropic Community Relations and Volunteer Contributions at San Diego's 2004 UN Day - 'Year of The Woman': PRNewswire - October 13, 2004; -- Actress Lindsay Wagner and Dr. Johns, UN New York Spokesperson, Among Those Attending the Event SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- The United Nations Association San Diego Chapter (UNA-SD), announced today that they will present their first ever UNA Global Corporate Citizenship Award to QUALCOMM Incorporat
Courteney Cox, David Arquette, Cynthia Nixon Among Celebrity Supporters of M.A.C AIDS Fund Holiday Card Program to Benefit Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - October 12, 2004; -- Children Affected by HIV/AIDS Created Artwork for Cards Which Support Services, Treatment for Kids Worldwide -- Kids Helping Kids Cards Perfect for Holiday Greetings, Stocking Stuffers NEW YORK, Oct. 12 /PRNewswire/ -- The M.A.C AIDS Fund Kids Helping Kids greeting cards is an annual project for the holiday season w
PowderMed Initiates a Phase I Clinical Trial for a Novel Therapeutic Herpes Simplex Type 2 (HSV2) DNA Vaccine: PRNewswire - October 12, 2004; OXFORD, England, October 12 /PRNewswire/ -- Phase I clinical trial in patients of therapeutic DNA vaccine for the treatment of HSV2 commences at The Centre for Clinical Studies in Houston, Texas using PowderMed s novel DNA-on-Gold technology PowderMed Ltd (PowderMed), a company focusing on the development of therapeuti
Generex Biotechnology Presents Information at the Euroconference Vaccines 3 Meeting of the Pasteur Institute in Paris on the Use of Novel Peptide Vaccine for Melanoma: PRNewswire - October 12, 2004; -- Transgenic Mice Studies with Genes for Human HLA-DR Support Potential Use of T-Helper Cell Peptide Vaccine for Cancers TORONTO, Oct. 12 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that Dr. Robert Humphreys, founder of its Antigen Express immunomedicines subsidiary, deli
AIDS NGOs Protest 40% Hikes in Drug Prices: PRNewswire - October 12, 2004; -- AIDS Advocates Ask Drug Companies to Incorporate South African Drug Pricing Regulations Without Increasing Single Exit Prices for NGOs & Further Limiting Access to Life-Saving Drugs DURBAN, South Africa, Oct. 12 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the United States largest AIDS organization which o
AHF Applauds L.A. County Supervisors' Vote for Names-Based Reporting of HIV Cases: PRNewswire - October 12, 2004; -- Board Votes 4 to 1 to Support Switch to Names-Based Reporting System to Replace Inefficient Unique Identifier Code-Based System Currently in Place; Move Now Requires Action by State Legislature -- Present System s Flaws Slow Tracking of HIV Case Numbers in L.A. & California; Inaccurate Numbers Contribute to Pote
UPDATE: AIDS Project Los Angeles, Celebrities to Honor AIDS Walk Founder and Commemorate 20 Years of the AIDS Walk Movement: PRNewswire - October 9, 2004; LOS ANGELES, Oct. 9 /PRNewswire/ -- AIDS Project Los Angeles (APLA) and hundreds of supporters, including a host of celebrities, will gather this Sunday to honor AIDS Walk originator Craig R. Miller, and mark the 20th year of the AIDS Walk movement. AIDS Walk Los Angeles, the world s first such event for HIV/AIDS, was
Health Journalism Seminar Scheduled for Buenos Aires, October 11-14, 2004: PRNewswire - October 8, 2004; BUENOS AIRES, Argentina , Oct. 8 /PRNewswire/ -- Leading international experts on HIV/AIDS will participate in a three-day seminar for Latin American journalists specializing in health coverage October 11-14, 2004. Among the speakers at the Journalism and Health seminar are Dr. Mario Valcarcel, an HIV/AIDS expert, Pan
POZ Magazine Says Bush-Cheney Continue to Ignore Truth About AIDS: November issue includes voter guide on HIV issues, endorses Kerry: PRNewswire - October 7, 2004; NEW YORK, Oct. 7 /PRNewswire/ -- In this week s debate, Vice President Richard Cheney admitted that he did not know the facts about the U.S. AIDS epidemic. Cheney said he was not aware of government statistics that African-American women are 13 times more likely to die of AIDS than their white peers. It was just one mo
FDA Grants Priority Review to Market Leader Pegasys(R) With Copegus(R) for Treatment of Hepatitis C in HIV Patients -- Signals Major Step Toward Satisfying Unmet Medical Need --: PRNewswire - October 6, 2004; NUTLEY, N.J., Oct. 6 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has granted a six-month Priority Review Status to the supplemental new biologics license application (sBLA) for Roche s combination therapy of Pegasys(R) (peginterferon alfa-2a) in combination with Copegus(R) (ribavirin, USP) for the tre
MedMira Hosts HIV/AIDS Seminars with Chinese CDC: Achieves Significant Progress in China Marketing Strategy: PRNewswire - October 6, 2004; HALIFAX, Oct. 6 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the global market leader in flow-through diagnostic technology, announced today that it has begun conducting a series of technical training seminars in collaboration with the Centers for Disease Control (CDC) in the Peop
AIDSVote.org Says Democrats and Republicans Still Need Aids 101 Education: Vice presidential debate highlights gap in understanding of U.S. epidemic: PRNewswire - October 6, 2004; NEW YORK, Oct. 6 /PRNewswire/ -- AIDSVote.org released the following statement today: When asked a clear, direct question by PBS Senior Correspondent Gwen Ifill about the U.S. HIV/AIDS epidemic during their debate, neither Vice President Cheney nor Senator Edwards gave a clear, direct answer. Both candidates responses
Fuzeon(R) Plus an Active Boosted Protease Inhibitor Doubles Long-Term Response in Treatment-Experienced HIV Patients: PRNewswire - October 5, 2004; NUTLEY, N.J., and DURHAM, N.C., Oct. 5 /PRNewswire-FirstCall/ -- Twice as many treatment-experienced patients who used Fuzeon(R) ( enfuvirtide ) with an active boosted protease inhibitor (PI) regimen experienced a significant virologic response when compared to patients on an active boosted PI regimen alone, according
Calypte Biomedical Announces Licensing Agreement with Ani Biotech: Agreement gives company worldwide freedom to operate for its rapid HIV platform: PRNewswire - October 5, 2004; PLEASANTON, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation today announced that it has entered into a worldwide licensing technology transfer and equipment purchase agreement with Ani Biotech (Ani). The agreement grants Calypte access to Ani s new patent pending rapid diagnostic test platform a
Life Extension Foundation Announces Its Support for the California Stem Cell and Cures Initiative - Proposition 71: PRNewswire - October 5, 2004; FORT LAUDERDALE, Fla., Oct. 5 /PRNewswire/ -- In agreement with major scientific organizations, dozens of Nobel Laureates and the majority of the scientific community, the non-profit Life Extension Foundation supports Proposition 71 -- the California Stem Cell and Cures Initiative. Life Extension stands firm in its eff
USAID Awards Global Alliance for TB Drug Development $8 Million Grant: PRNewswire - October 5, 2004; NEW YORK and WASHINGTON, Oct. 5 /PRNewswire/ -- The United States Agency for International Development (USAID) announced today an $8 million grant to the Global Alliance for TB Drug Development (TB Alliance) for research and development into new drugs to save lives and combat the rapid spread of TB infection, drug resi
Calypte Biomedical Receives Rapid Test HIV-2 Patent License From Bio-Rad: PRNewswire - October 4, 2004; PLEASANTON, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) announced today that it has entered into a worldwide, non-exclusive licensing agreement with Bio-Rad Laboratories (Amex: BIO and BIOb) for patents relating to the Human Immunodeficiency Virus, Type 2, or HIV-2. Bio-Rad is th
Medical Services' Shanghai Plant Begins Production for China: PRNewswire - October 4, 2004; EDMONTON, Alberta, Oct. 4 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has received permission to ship VScan HIV tests within China , prior to regulatory approval. The Company received an order for 50,000 VScan HIV test kits to be shipped within China.
AHF Disappointed That Schwarzenegger Vetoes Canadian Drug Bills: PRNewswire - September 30, 2004; SB 1333 (Perata, D, Oakland), Sponsored by AHF, Would Have Allowed Medi-Cal and the State s AIDS Drug Assistance Program (ADAP) to Reimburse Providers for Drugs Purchased From Canadian Pharmacies LOS ANGELES, Sept. 30 /PRNewswire/ -- California Governor Arnold Schwarzenegger today vetoed several pending OURx Bill of Ri
Female Condom Partners in China: PRNewswire - September 29, 2004; CHICAGO, Sept. 29 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) (FHC) announced that it has formed a new relationship with China s Beijing Zizhu Pharmaceutical Co. Ltd. (BZP). FHC and BZP signed a non-binding Letter of Understanding in which the two companies agreed to work together to
Trinity Biotech Receives FDA Approval for Uni-Gold(TM) Recombigen(R) HIV Test use With Fingerstick Wholeblood: PRNewswire - September 29, 2004; DUBLIN, Ireland , September 29 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) today announced it has received approval from the US Food & Drug Administration ( FDA ) for the use of its Uni-Gold(TM) Recombigen(R) HIV Test with finger stick whole blood samples.
The Immune Response Corporation Announces REMUNE(R) Restores HIV-1-Specific Activity of CD4+ and CD8+ T Cells, Similar to Anti-HIV Immune Responses Seen in Long-Term Nonprogressors - Results Published in September Issue of Journal of Experimental Medicine -: PRNewswire - September 28, 2004; CARLSBAD, Calif., Sept. 28 /PRNewswire-FirstCall/ -- An investigational treatment called REMUNE(R) (HIV-1 Immunogen) appears to boost both HIV-1-specific CD4+ and HIV-1-specific CD8+ T cell lymphocyte activity in chronically HIV-1 infected patients. The results are published in the September 20th issue of the Journal o
IPM enters into a Preliminary Agreement with GlaxoSmithKline to explore Potential of Anti-HIV Compounds as Microbicides: PRNewswire - September 24, 2004; SILVER SPRING, Md., Sept. 24 /PRNewswire/ -- The International Partnership for Microbicides (IPM) has announced that it has entered into a material transfer agreement with GlaxoSmithKline (GSK) under which GSK will select and provide proprietary anti-HIV compounds to be tested for possible use as microbicides. Gla
'Reducing the Probability of Error in HIV/AIDS Patient Care: A Workshop on Patient Safety, Medical Errors and Adverse Events': PRNewswire - September 24, 2004; Hyatt Regency San Francisco Hotel - September 24, 2004 San Francisco, California - 7:30 a.m. to 3:30 p.m. OAKLAND, Calif., Sept. 24 /PRNewswire/ -- The Institute of Medicine issued a landmark report several years ago that called for research and implementation of programs to avert preventable medical error. While there
IMF Undermines Fight Against AIDS, Says New Report: PRNewswire - September 23, 2004; WASHINGTON, Sept. 23 /PRNewswire/ -- In advance of the Annual Fall Meetings of the International Monetary Fund (IMF) and the World Bank, a new report accuses the IMF of undermining the fight against AIDS. The report by four humanitarian agencies says that despite the severity of the AIDS crisis, IMF restrictions on pub
Ukraine Will Improve Access to HIV/AIDS Treatment and Monitoring Through Partnership with Clinton HIV/AIDS Initiative: PRNewswire - September 23, 2004; KIEV, Ukraine , Sept. 23 /PRNewswire/ -- The Minister of Health of Ukraine, and the Clinton HIV/AIDS Initiative announced today that Ukraine has joined the Clinton HIV/AIDS Initiative Procurement Consortium. This partnership will pave the way for Ukraine to purchase high-quality AIDS medicines and diagnostics at the lo
South African Sales of MedMira Rapid HIV Tests Begin: Distributor Receives First Order and Launches Nationally: PRNewswire - September 23, 2004; HALIFAX, Sept. 23 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the international market leader in rapid flow- through diagnostic technology announced today that it has begun shipment of its MiraWell(TM) Rapid HIV Test to its distributor. Impilo Medical Supplies will be distributin
Bush Misleads UN about Support for Global Fund, Says Global AIDS Alliance: PRNewswire - September 21, 2004; WASHINGTON, Sept. 21 /PRNewswire/ -- Today at the United Nations President Bush is making a major speech highlighting his support for programs to address the global AIDS epidemic. Last Saturday in his Radio Address he proclaimed his support for the Global Fund, the world s premiere anti-AIDS effort, launched in 2001 at
Bush's UN Remarks on Global AIDS Program Seen as Window Dressing, Says AIDS Healthcare Foundation: PRNewswire - September 21, 2004; -- President s Remarks During UN Speech Mask PEPFAR s Dismal Performance to Date. $15B Relief Program Fails in Lives Saved ; ARV Treatment Goals Fall Far Short LOS ANGELES, Sept. 21 /PRNewswire/ -- At his speech during the opening of the United Nations General Assembly in New York this morning, President Bush touched b
MedMira Ships Rapid HIV Tests to Caribbean Distributor: Distributor Begins Active Sales of MedMira's Test to Hospitals: PRNewswire - September 21, 2004; HALIFAX, Sept. 21 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ: MMIRF) the market leader in flow-through diagnostics declared today it has begun shipment of it s MiraWell(TM) Rapid HIV Test to Caribbean Medical International (CMI). The rapid HIV test is intended for use in hospitals and c
Glaxo Drops Appeal in AIDS Drug Pricing Case, Says AHF: PRNewswire - September 21, 2004; -- British Drug Giant Backpedals on Vow to Appeal South African Competition Tribunal s Ruling Allowing Complaint Filed by AIDS Healthcare Foundation, US Largest AIDS Group, & South African AIDS Advocates to Proceed DURBAN, South Africa and LOS ANGELES, Sept. 21 /PRNewswire/ -- A landmark South African legal complai
AHF Hails California Governor for Signing Needle and Syringe Bill: PRNewswire - September 21, 2004; -- SB 1159 (Vasconsellos, D, Santa Clara) Creates Disease Prevention Demonstration Project Allowing Individuals to Purchase Up to 10 Hypodermic Needles & Syringes Without a Prescription. Governor Davis had Twice Vetoed Similar Measures; Schwarzenegger s Support Seen as Pragmatic Public Health Move LOS ANGELES, Sept
HIV Vaccine Trial moving to Enroll Last Cohort of Volunteers: PRNewswire - September 20, 2004; LOS ANGELES, Sept. 20 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced today that enrollment in the ongoing Phase I HIV vaccine clinical trial at UMMS is proceeding to the final cohort of participants.
ImmuKnow(TM), First and Only FDA-Cleared Cellular Assay For Measuring and Managing Immune System Health, Gains Attention at Prominent Conferences: PRNewswire - September 20, 2004; -- Cylex is First to Market with Test that Works to Lower the Cost of Healthcare and Improve Therapeutic Outcomes in Transplantation and Infectious Disease Markets COLUMBIA, Md., Sept. 20 /PRNewswire/ -- Cylex Incorporated, today announced that ImmuKnow(TM), the first and only FDA-cleared cellular assay for measuring a
Radio Address By President Bush to the Nation: PRNewswire - September 18, 2004; WASHINGTON, Sept. 18 /PRNewswire/ -- The following is a transcript of remarks by President Bush to the nation. THE PRESIDENT: Good morning. Three years after the attacks of September the 11th, our nation continues to confront the threats to our security. We re acting to protect the homeland, to track and disrupt terror
WHO Urges Member States to Act Now to Avoid a Major HIV/AIDS Epidemic: Fifty-Fifth Session of the WHO Regional Committee for the Western Pacific 13-17 September 2004, Shanghai, China: PRNewswire - September 17, 2004; SHANGHAI, China , Sept. 17 /Xinhua-PRNewswire/ -- Dr Shigeru Omi, World Health Organization Regional Director for the Western Pacific, has warned of the danger of HIV bridging into the general population from infected individuals with high-risk behaviour unless countries and areas in the Region act now to avoid a major
WHO: Urgent Action is Required to Meet 2005 Case Detection Target: Fifty-fifth Session of the WHO Regional Committee 13-17 September 2004, Shanghai, China: PRNewswire - September 17, 2004; SHANGHAI, China , Sept. 17 /Xinhua-PRNewswire/ -- Countries must accelerate their efforts now if the Western Pacific Region* is to reach the target of a 70% case detection rate by the end of 2005. This is a very important milestone. It is the first step towards the 2010 objective of reducing the burden of tuberculosis
WHO: Protect the Public From Contaminated Blood: PRNewswire - September 17, 2004; -- Fifty-fifth Session of the WHO Regional Committee 13-17 September 2004, Shanghai, China SHANGHAI, China, Sept. 17 /Xinhua-PRNewswire/ -- Urgent measures need to be taken to protect the public from contaminated blood transfusions, the World Health Organization (WHO) warned today. In the Western Pacific Region
Bush AIDS Plan Reaches 1.25% of Treatment Goal: PRNewswire - September 14, 2004; WASHINGTON, Sept. 14 /PRNewswire/ -- Global AIDS Alliance reacted today to the statement of the Bush Administration regarding its global AIDS programs. The Administration says it is providing AIDS treatment to 25,000 people through its own programs as well as its contributions to other AIDS programs. This figure repres
New Economic Study Demonstrates Proposition 71 Benefits to State Economy: Investment in Stem Cell Research Could Yield More Than $12 Billion in Returns: PRNewswire - September 14, 2004; Through Tax Revenues, Royalty Revenues, and Health Care Cost Savings LOS ANGELES, Sept. 14 /PRNewswire/ -- A new economic study, co-authored by a nationally-recognized economic research firm, the Analysis Group, and Stanford professor and economist Dr. Laurence Baker, has determined that Proposition 71, the stem cell r
Sangamo BioSciences Updates Investors on Status of Latest Developments in ZFP Therapeutics Programs: Details of Programs in Diabetic Neuropathy and HIV Announced: PRNewswire - September 14, 2004; RICHMOND, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Sangamo BioSciences (Nasdaq: SGMO) will provide an update today to investors on the status of the latest developments in several of its ZFP Therapeutics programs. Scientists from the Company will provide details on programs focused on diabetic neuropathy (DN) and a n
The Immune Response Corporation Presents New Phase II Clinical Data Indicating That REMUNE(R) Induces a HIV-Specific Immune Response: PRNewswire - September 14, 2004; -- Interim Results From Study in Italy in Drug-Naive HIV Patients Presented at HIV Meeting CARLSBAD, Calif., Sept. 14 /PRNewswire-FirstCall/ -- An investigational treatment, REMUNE(R) (HIV-1 Immunogen), induces HIV-specific immunity in drug-naive patients according to interim results from an ongoing multi-center Phase
The Philadelphia AIDS Consortium's Access to Care Through Service (ACTS) Will Provide Another Three Years of Excellent Service to the HIV/AIDS Community: PRNewswire - September 14, 2004; -- One Million Dollar Grant is Awarded to TPAC s ACTS AmeriCorps Program by the Corporation of National and Community Service PHILADELPHIA, Sept. 14 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC), a local nonprofit organization and major funder of support services to individuals with HIV/AIDS, announces offici
Bush Global AIDS Plan Results Called 'Failure' by AIDS Healthcare Foundation: Only 5% of Treatment Goal Set by Congress Has Been Met: PRNewswire - September 13, 2004; LOS ANGELES, Sept. 13 /PRNewswire/ -- AIDS Healthcare Foundation released the following statement in response to a Washington Post article noting 25,000 AIDS patients are in treatment under President Bush s global AIDS plan: Congress set global AIDS treatment goals in federal law last year, but today s numbers indicate
Gay Men's Health Crisis Compares Healthcare Positions of Presidential Candidates Bush and Kerry: PRNewswire - September 13, 2004; NEW YORK, Sept. 13 /PRNewswire/ -- Gay Men s Health Crisis (GMHC) today released a report that compares the health care reform proposals of President George W. Bush and Senator John Kerry. Entitled Prescriptions for Reform: A Comparison of the Bush and Kerry Health Care Access Proposals and their Impact on People with
Barnett Releases State Clinical Trial Requirements Reference Guide: PRNewswire - September 13, 2004; PHILADELPHIA, Sept. 13 /PRNewswire-FirstCall/ -- Barnett Educational Services, a division of PAREXEL International Corporation (Nasdaq: PRXL), has announced the release of State-by-State Clinical Trial Requirements Reference Guide. Designed for clinical research professionals, regulatory affairs professionals, clinical
The Immune Response Corporation Announces Clinical Trial for HIV Therapy IR103 Has Begun to Enroll: First HIV Patients Enrolled in New International Trial: PRNewswire - September 10, 2004; CARLSBAD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today the first patients have been enrolled at the Canadian site in its initial clinical
Chiron Announces Settlement with Roche in HIV Patent Dispute: Agreement Highlights Strength of Company's Intellectual Property Estate: PRNewswire - September 10, 2004; EMERYVILLE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under a licensing agreement related to its U.S. Pate
The U.S. Fund for UNICEF and Procter & Gamble Reunite To Help Children in Latin America: PRNewswire - September 9, 2004; -- Campaign Seeks to Raise Funds for UNICEF Programs in Latin America through the Purchase of Bounce(R), Bounty(R), Charmin(R), Dawn(R) and Downy(R) NEW YORK, Sept. 9 /PRNewswire/ -- For the fifth consecutive year, the U.S. Fund for UNICEF and Procter & Gamble (P&G) brands are coming together to provide childre
Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C: PRNewswire - September 7, 2004; CAMBRIDGE, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has successfully completed the dosing portion of a Phase Ia clinical trial for VX-950, an investigational oral protease inhibitor for the treatment of hepatitis C virus (HCV) infection. The study, i
Roche Files Application with FDA to Market Leading Hepatitis C Medication Pegasys(R) in Combination with Copegus(R) for People with HIV - Hepatitis C, a major killer of Americans with HIV, afflicts 30 percent of U.S. HIV population -: PRNewswire - September 2, 2004; NUTLEY, N.J., Sept. 2 /PRNewswire/ -- Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) in combination with Copegus(R) (ribavirin, USP) for the treatment of chronic hepatitis C in patien
AHF Sues Glaxo for AIDS Drug Price Gouging: PRNewswire - September 2, 2004; LOS ANGELES, CA USA 04/29/2003 - AIDS HealthCare Foundation Files Federal Action Seeking Damages From British Drug Giant Over Fraud in Glaxo s Drug Pricing Practices in US Government s 340B Drug Discount Program. AIDS Group Will Also Ask Senator Richard Alarcon to Spearhead State Legislative Audit Based on Glaxo s Agre
India's Swami Vivekananda Youth Movement (SVYM) Partners With AIDS Healthcare Foundation Global Immunity (AHF-GI) in New AIDS Treatment Clinics in Karnataka State, India: PRNewswire - September 1, 2004; LOS ANGELES, CA USA 04/29/2003 Partnership of US Largest AIDS Group, Respected Indian NGO, and Indian State Government Hospital to Bring Life-Saving ARVs to Patients in Mysore & Koppal LOS ANGELES, Sept. 1 /PRNewswire/ -- AIDS Healthcare Foundation, (AHF) the largest AIDS organization in the United States
Aids Vaccine '04 Conference Calls for a Coherent Research Strategy at European Level to Fight HIV Pandemic: Leading Scientists Urge EUROPEAN Countries to Greater Commitment: PRNewswire - September 1, 2004; LAUSANNE, Switzerland , September 1 /PRNewswire/ -- At the close of the AIDS VACCINE 04 Conference, leading scientists called for both a coherent research strategy to fight the HIV/AIDS pandemic and increased financial commitment with appropriate resources, planning and implementation at European Commission and EFTA co
Testing With Procleix(R) West Nile Virus Assay Initiated on Procleix(R) TIGRIS(R) System Under IND: Automated System Provides Blood Centers with Highest Process Control for Testing: PRNewswire - September 1, 2004; EMERYVILLE, Calif. and SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Chiron (Nasdaq: CHIR) and Gen-Probe (Nasdaq: GPRO) announced today that testing with the Procleix(R) West Nile Virus (WNV) Assay has been initiated under an investigational protocol on the Procleix(R) TIGRIS(R) System. The high-throughput, fully automa
United Nations Foundation President Articulates International Right to Protection: PRNewswire - September 1, 2004; Former US Senator Timothy E. Wirth Calls for Implementation of ICPD Action Plan to Alleviate Fear, Poverty; Urges Conference Attendees to Support Integrated Approach to Reproductive Health, HIV/Aids and Millennium Development Goals So All People Can Protect Themselves LONDON, Sept. 1 /PRNewswire/ -- Timothy E. Wirth, P
Epimmune Presents SIV Vaccine Study Data at AIDS Vaccine 2004 in Lausanne, Switzerland Showing Control of Virus Despite the Presence of Viral Mutations: PRNewswire - August 31, 2004; SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today presented preliminary data from its ongoing SIV rhesus macaque vaccine study at the AIDS Vaccine 2004 conference in Lausanne, Switzerland . SIV is the virus equivalent of HIV in many non-human primate species. Preliminary data presented sh
Remarks by Senator Sam Brownback on 'AIDS Initiative' as Prepared for Delivery at the 2004 Republican National Convention on Tuesday, August 31, Evening Session 7:00 - 11:15 P.M. EDT: PRNewswire - August 31, 2004; NEW YORK, Aug. 31 /PRNewswire/ -- The following are remarks by Senator Sam Brownback on AIDS Initiative as prepared for delivery at the 2004 Republican National Convention: My friends, it is a privilege to be with you. A fundamental principle of our democracy and our Republican Party is respect for the inherent dignity
AIDS VACCINE '04 Conference Calls for Increased Political and Financial Commitment: At Least 1 Billion Euros Yearly Required: PRNewswire - August 30, 2004; LAUSANNE, Switzerland , August 30 /PRNewswire/ -- At the opening ceremony of the Lausanne, Switzerland, AIDS VACCINE 04 conference, leaders in the field of AIDS vaccine research called for increased political and financial commitment to facilitate the development of preventive and therapeutic AIDS vaccines as a public
AIDS VACCINE '04 Conference Calls for Increased Political and Financial Commitment: At Least 1 Billion Euros Yearly Required: PRNewswire - August 30, 2004; LAUSANNE, Switzerland , August 30 /PRNewswire/ -- At the opening ceremony of the Lausanne, Switzerland, AIDS VACCINE 04 conference, leaders in the field of AIDS vaccine research called for increased political and financial commitment to facilitate the development of preventive and therapeutic AIDS vaccines as a public
Gay Issues and the 2004 Election: PRNewswire - August 27, 2004; WASHINGTON, Aug. 27 /PRNewswire/ -- The Human Rights Campaign (HRC) is the nation s largest gay, lesbian, bisexual and transgender advocacy organization, with 600,000 members, a 110-person staff, three governing boards, a national headquarters building in downtown Washington, D.C., and a $30 million annual budget. In 2
New Long-Term Data Provide Guidance on the Use of Sustiva(R) (Efavirenz) in HIV-Treatment-Naive Patients: PRNewswire - August 26, 2004; -- Package Insert to Include 168-Week Data on Long-Term Durability, Safety & Tolerability - PRINCETON, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that SUSTIVA(R) ( efavirenz ) has received approval from the U.S. Food and Drug Administration (
Theratechnologies presents results from its HIV-associated lipodystrophy Phase II study on ThGRF at the 12th International Congress of Endocrinology: PRNewswire - August 26, 2004; -- Additional presentations to be made before year end in Europe and the US MONTREAL, Aug. 26 /PRNewswire-FirstCall/ - Theratechnologies (TSX :TH) announced today that results of its Phase II clinical trial on ThGRF in patients with HIV-related lipodystrophy, a medical condition characterized by body composition change
Bavarian Nordic Announces Significant Progress in Safe Smallpox Vaccine: Company Strengthens its Position in Competition for NIH Award: PRNewswire - August 26, 2004; COPENHAGEN, Denmark and WASHINGTON, Aug. 26 /PRNewswire/ -- International biopharmaceutical company Bavarian Nordic announced today its interim results for the six-month period ending 30 June, 2004, and other key developments. Bavarian Nordic noted particular progress has been made to date on their safe, third generati
Leading AIDS Organizations Launch Absentee Ballot Drive: Requests for Ballots and Voter Registration Available Online at POZ.com: PRNewswire - August 25, 2004; NEW YORK, Aug. 25 /PRNewswire/ -- A coalition of leading AIDS organizations today announced the launch of a major absentee ballot drive for the 2004 elections through POZ.com. Using new interactive technology, visitors to POZ.com can now request absentee ballots, register to vote and change their registered addresses.
Viral Genetics Appoints Former U.S. Surgeon General Dr. Jocelyn Elders to Scientific and Medical Advisory Board: PRNewswire - August 25, 2004; AZUSA, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Viral Genetics (OTC Bulletin Board: VRAL) is pleased to announce the addition of Dr. Jocelyn Elders to its Scientific and Medical Advisory Board. Dr. Elders has a long and distinguished track record of public health service, most notably as Surgeon General of the U.S. Pu
HIV-Positive Children in Resource-Limited Setting Successfully Treated: PRNewswire - August 23, 2004; HOUSTON, Aug. 23 /PRNewswire/ -- Clinicians have been able to reduce mortality rates in HIV positive children from 15 to 3 percent in the largest group of children treated with highly active antiretroviral therapy (HAART) in any single center worldwide, according to a paper published in the August 2004 issue of The Ped
Medarex Announces Special Protocol Assessment Agreement with FDA to Initiate Phase III Clinical Trial for MDX-010 in Metastatic Melanoma: PRNewswire - August 23, 2004; -- Conference Call Scheduled for 11:00 AM ET Today to Discuss Phase III Trial PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration ( FDA ) for the initiation of a pi
Generex Biotechnology Expands HIV Vaccine Efforts With Leading MGH Investigator: Collaboration to Study Patient's Recognition of Novel Vaccine Stimulating T-Helper Cells: PRNewswire - August 18, 2004; TORONTO, Aug. 18 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that its wholly owned subsidiary, Antigen Express, has established a collaboration with Massachusetts General Hospital to use modified peptide antigens to stimulate immunity to HIV for both prevention and treatme
California Mayors & Local Elected Officials Endorse Proposition 71: Noting Measure's Promise to Save Lives and Boost Local Economies: PRNewswire - August 18, 2004; -- Los Angeles City Council Votes Unanimously to Lend Support to Prop. 71 LOS ANGELES, Aug. 18 /PRNewswire/ -- Supporters of Proposition 71, the California Stem Cell Research and Cures Initiative, today announced that mayors and local elected officials across California have endorsed the measure, adding to a growing, b
Nomination Introduces Red Ribbon Charm to Support The American Foundation for AIDS Research (amfAR): PRNewswire - August 18, 2004; NEW YORK, Aug. 18 /PRNewswire/ -- Nomination, the original creator of the composable charm bracelet, introduces the red ribbon charm link symbolizing AIDS prevention and awareness and support of amfAR -- the nation s leading nonprofit organization dedicated to the support of AIDS research. Nomination has planned a nati
MedMira Rapid HIV Tests Donated to African Orphanage: Supporting Canadian Hopes and Dreams Team to Provide HIV Testing for Orphaned Children in Kenya: PRNewswire - August 17, 2004; HALIFAX, Aug. 17 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF), the market leader in rapid flow-through diagnostic technology, announced today that it has donated MiraWell(TM) Rapid HIV Tests to the Hopes and Dreams Team for use in Kenya at an orphanage where over 700 orphaned child
Investigational Formulation of Invirase(R) Granted Priority Review Status by U.S. FDA - 500 mg Tablet to Simplify Drug Regimens -: PRNewswire - August 17, 2004; NUTLEY, N.J., Aug. 17 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration ( FDA ) has granted priority review status to the New Drug Application (NDA) for a 500 mg tablet formulation of its HIV protease inhibitor, Invirase (R) (saquinavir mesylate). If approved, the new formulation of In
2004 World Factbook Now Available From NTIS: Basic Intelligence on All Areas of the World Released by the CIA in One Handy Manual: PRNewswire - August 17, 2004; SPRINGFIELD, Va., Aug. 17 /PRNewswire/ -- The World Factbook, a popular Central Intelligence Agency reference manual, provides a wealth of information on over 260 separate nations and other entities, listed alphabetically, in over 700 pages. There are also 11 terrain maps and three world maps included. The World Factbo
AHF: Generic AIDS Medications Backed by California and Mexican Leaders: PRNewswire - August 13, 2004; -- NAFTA Issues Discussed at Legislative Forum: Pledge Made to Work Together to Lift Trade Barriers to Cost Effective, Life-Saving HIV Treatment SACRAMENTO, Aug. 13 /PRNewswire/ -- A special meeting of Legislators from the 3 Californias, yesterday pledged to advocate for access to low cost, generic AIDS medications in
MedMira Rapid HIV Test Number One In U.S. Hospitals: Recent CDC Study Shows MedMira is a Leader in the Point-Of-Care Market: PRNewswire - August 12, 2004; HALIFAX, Aug. 12 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the market leader in flow-through diagnostics today announced its Reveal(TM) Rapid HIV-1 Antibody Test is the number one choice of hospitals in the United States (where over 80% of HIV testing is conducted) according to
New Survey Reveals Surprising Insights into Parental Attitudes Toward Teenage Sexual Behavior: Parents Share Top Concerns About Their High Schoolers: PRNewswire - August 11, 2004; BLUE SPRINGS, Mo., Aug. 11,2004 /PRNewswire/ -- As an estimated four million American children make the transition from junior high/middle school to high school this fall, a new national survey conducted by the Society for Adolescent Medicine (SAM) reveals parents primary concerns as they ready their teenagers for the
New 3- Minute Rapid HIV Test Launched In United States: Reveal(TM) G2 Introduced at AACC in Los Angeles: PRNewswire - August 10, 2004; HALIFAX, Aug. 10 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR, NASDAQ:MMIRF) the market leader in flow-through diagnostics today announced the U.S. launch of its newest FDA approved rapid HIV test, the Reveal(TM) G2 Rapid HIV-1 Antibody Test (Reveal(TM) G2) at the AACC (American Association for C
Detroit Area Artists Unite in the Fight Against AIDS: PRNewswire - August 10, 2004; FERNDALE, Mich., Aug. 10 /PRNewswire/ -- Over 300 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the ninth annual ART WORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 18, 2004 at Detroit s historic Masonic Temple to benefit the Midwest AIDS Pr
Calypte Biomedical Announces Signing of Sublicense Agreement with Abbott Laboratories: PRNewswire - August 9, 2004; PLEASANTON, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), announced today that it has signed a sublicense agreement with Abbott Laboratories , Inc. (NYSE: ABT) for certain worldwide rights to patents relating to the design, manufacture and sale of lateral-flow rapid
AHF AIDS Program Saves Florida $52 Million: PRNewswire - August 9, 2004; -- AHF is Shining Star in Otherwise Troubled Disease Management Initiative: Program Improved Patient Health Outcomes While Reducing State s Costs Significantly WHAT: Media Availability -- On $52M Savings to Florida s MediPass (Medicaid) Program and Improved Patient Outcomes by AIDS Healthcare Foundation s Disease Manag
FDA Advisory Committee Overwhelmingly Recommends Approval of Roche's COBAS AmpliScreen Hepatitis B Test for Use in Screening Donated Whole Blood: Test Is First Nucleic Acid Hepatitis B Blood Screening Test to Be Accepted For Review by FDA: PRNewswire - August 9, 2004; PLEASANTON, Calif., Aug. 9 /PRNewswire/ -- Roche Diagnostics announced that the Blood Products Advisory Committee (BPAC) of the United States Food and Drug Administration ( FDA ) voted overwhelmingly that the sensitivity and specificity of Roche s COBAS AmpliScreen HBV Test in a mini-pool format supported licensing as
Generic Drugs Work: Proof is Seen in the WHO's Pulling of Ranbaxy Drugs, Says AHF: PRNewswire - August 6, 2004; -- As the Heated Debate Over the Use of Generics in the Developing World Continues, the World Health Organization Takes Steps to Ensure the Health and Safety of Millions Living With HIV by Pulling Three Drugs off its List of Approved Medicines LOS ANGELES, Aug. 6 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the la
New Survey Finds Majority of African Americans Say U.S. is Losing Ground on HIV/AIDS: African Americans Name HIV/AIDS the Most Urgent Health Problem, While Latinos Place It the Second Most Urgent Behind Cancer: PRNewswire - August 4, 2004; WASHINGTON, Aug. 4 /PRNewswire/ -- A majority of African Americans (56%) say the U.S. is losing ground when it comes to the problem of HIV/AIDS -- an 18 percentage point increase since October 2003 -- according to a new national survey by the Kaiser Family Foundation, conducted this spring. By comparison, three in ten
Medical Discoveries Inc. Announces Multiple Clinical Development Priorities Under a Drug Master File: PRNewswire - August 4, 2004; TWIN FALLS, Idaho, Aug. 4 /PRNewswire-FirstCall/ -- Medical Discoveries, Inc. (OTC Bulletin Board as MLSC) announced today an addition in clinical development priorities to multiple indications, led by Cystic Fibrosis (CF) and HIV, as allowed under an FDA Drug Master File (DMF). The Company s clinical development objec
Viral Genetics Announces Enrollment for South African Clinical Trial of VGV-1: Clinical Trial Funding Support Tied to Distribution Agreement and Subsidiary Sale: Company to focus on development in USA: PRNewswire - August 3, 2004; AZUSA, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (OTC Bulletin Board : VRAL) (the Company ) today announced that enrollment has begun for a human clinical trial in South Africa on VGV-1. VGV-1 (formerly known as Thymus Nuclear Protein) is a purified protein extracted from bovine thymus gland that ha
AHF Thanks Governor and Legislature for Compromise on Funding for Vital AIDS Testing Program: 2004-2005 Budget Includes $4 Million for Essential Viral Load Monitoring: PRNewswire - August 3, 2004; LOS ANGELES, Aug. 3 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest HIV organization, welcomes the recent inclusion of $4 million to a General Fund program specifically earmarked for viral load and HIV resistance testing, in the final 04-05 budget. Last year, $7 million was cut from the $8 millio
Trinity Biotech Receives FDA Clearance for CAPTIA(TM) Herpes Simplex Virus (HSV) IgG Type Specific ELISAs: PRNewswire - August 3, 2004; DUBLIN, Ireland , August 3 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB) announced that it has received clearance from the U.S.A. Food and Drug Administration ( FDA ) to market its CAPTIA(TM) HSV IgG Type Specific ELISAs in the United States .
FDA Approves EPZICOM - A New HIV Medication Combining Two Antiretrovirals in One Tablet Dosed Once a Day: PRNewswire - August 2, 2004; RESEARCH TRIANGLE PARK, N.C., Aug. 2 /PRNewswire/ -- EPZICOM(TM), a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration ( FDA ). EPZICOM combines two widely-used nucleoside rever
Epimmune Reports Data in The Journal of Immunology Showing Cellular Response Against Multiple HIV Variants and Subtypes With Epitope Vaccine: PRNewswire - August 2, 2004; SAN DIEGO, Aug. 2 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today announced the publication of data in the August 1 issue of The Journal of Immunology which showed that an epitope-based HIV-1 vaccine can be designed to induce cytotoxic T lymphocytes (CTL) capable of recognizing viruses from different parts
From Bangkok to Toronto: The Tough Road Ahead in The Campaign to Combat HIV/AIDS: PRNewswire - August 2, 2004; MANILA, Philippines , Aug. 2 /Xinhua-PRNewswire/ -- HIV/AIDS is still a major global emergency, which must remain at the forefront of policy-makers priorities. That was the over-riding message of the 15th International AIDS Conference in Bangkok, Thailand in July 2004 and it is a message that will be repeated
Giving Aid to the Children; Compassion International Expands AIDS Assistance to Children: PRNewswire - August 2, 2004; COLORADO SPRINGS, Colo., Aug. 2 /PRNewswire/ -- Compassion International, one of the world s largest child development organizations, is significantly increasing its help to children infected with the HIV/AIDS virus. The ministry intends to triple the amount of money it spends over the next three years, making new drug
Ranbaxy to File ARVs With the US FDA: PRNewswire - August 2, 2004; NEW DELHI, India , Aug. 2 /PRNewswire-FirstCall/ -- In response to the many enquiries the Company has been receiving in the recent past, Ranbaxy Laboratories Limited (Ranbaxy) has initiated a program to file its Anti Retroviral (ARV) range of products for the treatment of HIV/AIDS with the US
AIDS Healthcare Foundation Press Release; Schwarzenegger Vetoes AIDS Pharmacy Funds: PRNewswire - July 31, 2004; LOS ANGELES, July 31 /PRNewswire/ -- California Governor Arnold Schwarzenegger today used his line item veto power to kill a legislative effort protecting AIDS patients from across-the-board pharmacy budget cuts, according to the AIDS Healthcare Foundation, the US largest HIV organization. We are deeply disappointed to
GenVec and NIH Move HIV Vaccine Candidate Into Human Clinical Trials: NIH Initiates Phase I HIV Vaccine Trial: PRNewswire - July 28, 2004; GAITHERSBURG, Md., July 28 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC), announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has initiated a Phase I clinical study to test an HIV vaccine candidate
New England Journal of Medicine Publishes Results from Landmark Study Reporting the Highest Response Rates Ever Achieved for the Treatment of Hepatitis C in Co-infected Patients: PRNewswire - July 28, 2004; -- Study Findings Offer New Hope for the Estimated 300,000 Americans Co-infected With Hepatitis C and HIV NEW YORK, July 28 /PRNewswire/ -- A landmark study published in this week s New England Journal of Medicine reveals the highest efficacy rates ever reported among patients co-infected with hepatitis C and HIV treat
Landmark Study Published in New England Journal of Medicine Shows 40 Percent of People Infected with HIV and Hepatitis C had Sustained Response to Pegasys Hepatitis C Combination Therapy: PRNewswire - July 28, 2004; NUTLEY, N.J., July 28 /PRNewswire/ -- A landmark study published today in the New England Journal of Medicine showed that 40 percent of people with chronic hepatitis C co-infected with HIV who were treated with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin), achieved a sustained virological response (a p
Lingerie Bowl 2005 and AIDS Research Alliance of America Will Team on Super Bowl Sunday in the Fight Against AIDS: National Charity Will Benefit From PPV Broadcast: PRNewswire - July 27, 2004; LOS ANGELES, July 27 /PRNewswire/ -- Horizon Productions, Inc. is proud to announce that Pay-Per-View sales from the Lingerie Football League s (LFL) second annual Super Bowl halftime alternative Lingerie Bowl 2005 (http://www.lingeriebowl.com) will benefit the AIDS Research Alliance of America (http://www.aidsresearch
Generex Biotechnology Presents Research Abstract on the Use of Novel Peptide Vaccine for Melanoma at the 12th International Congress of Immunology: Late Preclinical Studies Support Potential Use of T-Helper Cell Peptide Vaccine for Cancers: PRNewswire - July 27, 2004; TORONTO, July 27 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), announced today the presentation of a research abstract by Cathy Blackwell of its Antigen Express immunomedicines subsidiary at the 12th International Congress of Immunology and 4th Annual Conference of FOCIS in Montreal. Cathy
The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103 - REMUNE(R) and IR103 Development on Track -: PRNewswire - July 27, 2004; CARLSBAD, Calif., July 27 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), presented research results at the International Congress of Immunology in Montreal demonstratin
10th Annual National HIV Testing Day Big Hit: Public-Private Partnership and National Community Support Vital to Success: PRNewswire - July 27, 2004; WASHINGTON, July 27 /PRNewswire/ -- Thousands of Americans received voluntary HIV counseling and testing across the country during the days leading up to and following June 27, making this year s National HIV Testing Day (NHTD) one of the most successful in the 10-year history of the event. The National Association of
Abbott Laboratories Announces Submission for Once-Daily Kaletra(R) (lopinavir/ritonavir) in United States, Europe - Application Seeks Use as Part of a Combination Regimen in HIV Treatment-Naive Patients: PRNewswire - July 26, 2004; ABBOTT PARK, Ill., July 26 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration ( FDA ) and a Marketing Authorization variation to the European Medicines Agency (EMA), seeking approval of once-daily d
BET'S Rap-It-Up Hosts David Deal Playday BET Teen Concert on August 4: PRNewswire - July 26, 2004; WASHINGTON, July 26 /PRNewswire/ -- BET s Rap-It-Up, the cable network s national HIV/AIDS public awareness initiative, comes to Fort Lauderdale to host the David Deal Playday/BET Teen Concert in partnership with the City of Fort Lauderdale and local radio station, 103.5 The Beat. BET s Rap-It-Up, along with the Browar
BET'S Rap-It-Up Sponsors Teen Forum & Testing for Tickets During Magic Johnson's 19th Annual 'A Midsummer Night's Magic' in LA, July 31 - August 1: PRNewswire - July 26, 2004; LOS ANGELES, July 26 /PRNewswire/ -- BET s Rap-It-Up, returns to Los Angeles with its award-winning, national HIV/AIDS initiative to host a teen forum during Earvin Magic Johnson s 19th Annual A Midsummer Night s Magic, July 30 - August 1. Committed to raising awareness about HIV/AIDS, Rap-It-Up will host a teen forum
BET, Black AIDS Institute and Kaiser Family Foundation Announce Winners of Rap-It-Up/Black AIDS Short Subject Film Competition: PRNewswire - July 26, 2004; WASHINGTON, July 26 /PRNewswire/ -- Concluding an extensive national call for submissions and thorough review process, Black Entertainment Television (BET), the Black AIDS Institute (The Institute), and the Kaiser Family Foundation proudly announce today the winners in the Rap-It-Up/Black AIDS Short Subject Film Compet
Gay Issues and the 2004 Election: PRNewswire - July 23, 2004; WASHINGTON, July 23 /PRNewswire/ -- The Human Rights Campaign (HRC) is the nation s largest gay, lesbian, bisexual and transgender advocacy organization, with 600,000 members, a 110-person staff, three governing boards, a national headquarters building in downtown Washington, D.C., and a $30 million annual budget. In 2
Viral Genetics Announces Results of Chinese Study of VGV-1 for the Treatment of AIDS: China Study Shows Sustained HIV Virus Suppression in Treatment-Naive AIDS Patients: PRNewswire - July 23, 2004; AZUSA, Calif., July 23 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (OTC Bulletin Board: VRAL) today announced the results of the human clinical trial conducted in China at the National AIDS Center located in Beijing Ditan Hospital. The results suggest that patients receiving no additional anti-HIV therapy had sustai
Stressgen Presents Data at International Immunology Congress -- Immunization with HspE7 Induces Strong and Durable Cellular Response to HPV E7 Protein in Normal and Immunocompromised Mice: PRNewswire - July 22, 2004; MONTREAL, July 22 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation (TSX:SSB) today presented data at the 12th International Congress of Immunology demonstrating that HspE7, the Company s lead immunotherapeutic, induces strong and durable cellular responses to the human papillomavirus (HPV) E7 protein in n
Roche Files for Application with FDA to Market Leading Hepatitis C Medication Pegasys(R) for Chronic Hepatitis B Treatment - CDC Estimates 1.25 Million in U.S. are Chronically Infected with Hepatitis B: PRNewswire - July 21, 2004; NUTLEY, N.J., July 21 /PRNewswire/ -- Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis B (CHB). Simultaneously, Roche has also filed with the Euro
Bioject Signs Agreement With Path to Develop and Evaluate a Disposable- Cartridge Jet Injection System for Global Immunization: PRNewswire - July 19, 2004; BEDMINSTER, N.J., July 19 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, announced today that it has signed a collaboration agreement with PATH, an international nonprofit organization whose mission is to improve the health of people
GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV: PRNewswire - July 16, 2004; LONDON, July 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received marketing approval from the European Commission for Telzir(R) ( fosamprenavir ) for the treatment of HIV infection in adults in combination with other anti-HI
AIDS Healthcare Foundation and Abbott Laboratories Agree to Collaborate on Programs to Support HIV Community; Resolve Lawsuits: PRNewswire - July 16, 2004; BANGKOK, Thailand , July 16 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) and Abbott Laboratories have agreed to work together on enhanced AIDS prevention, diagnosis and treatment programs. The agreement resolves the two lawsuits brought by AHF against Abbott over the company s price increase for its HIV/AIDS drug,
Bayer Healthcare Reaffirms Commitment to Community, People Living with AIDS; Lends Support for AIDS Walk San Francisco and 'KidZone': PRNewswire - July 16, 2004; TARRYTOWN, N.Y., July 16 /PRNewswire/ -- Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY), announced today that it is a proud sponsor of the San Francisco AIDS Walk. Specifically, Bayer HealthCare has provided the resources necessary for the group to implement KidZone, the first-ever family oriented initia
Calypte Biomedical Presents Results of Its Rapid HIV-1/2 Field Trial Tests at the XV International AIDS Conference in Bangkok: Overall Accuracy: Blood Rapid 100%, Oral Fluid Rapid 99.8%, Urine Rapid 99.6%: PRNewswire - July 15, 2004; PLEASANTON, Calif., July 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) announced today that it has completed the initial field trials of its rapid products currently under development and has distributed that study data at the XV International AIDS Conference in Bangkok,
Novation Signs Agreement With Bayer Diagnostics for Molecular Diagnostics Products: PRNewswire - July 15, 2004; IRVING, Texas, July 15 /PRNewswire/ -- Novation, the supply company of VHA Inc. and the University HealthSystem Consortium, has signed an agreement with Bayer HealthCare LLC, Diagnostics (NYSE: BAY) for molecular diagnostics products and accessories. The agreement took effect on June 15, 2004, and runs through June 14,
The Immune Response Corporation Presents Data Demonstrating IR103 HIV-Specific Immunologic Activity at XV International AIDS Conference - IR103 Produces HIV-Specific Immune Responses in Saline Formulation -: PRNewswire - July 15, 2004; CARLSBAD, Calif., July 15 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced that research results suggest its newest HIV product candidate, IR103, generated robu
Jewel to Perform at Summer Party(TM) for AIDS Project Los Angeles: PRNewswire - July 14, 2004; LOS ANGELES, July 14 /PRNewswire/ -- APLA s Summer Party(TM) is set to re-launch at a new location, Paramount Studios, on Saturday, July 24 from 7 P.M. until midnight. Singer/songwriter Jewel has signed on to headline a musical bill to include Robi Draco Rosa and Paul Lekakis. Master promoter Tom Whitman will present
Procleix(R) Ultrio(TM) Study Presented at International Society of Blood Transfusion Conference - Data Highlight the Value of Ultrio - Hepatitis B-Positive Blood Donation Detected: PRNewswire - July 14, 2004; EMERYVILLE, Calif., July 14 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced the results of a multicenter trial of the Procleix(R) Ultrio(TM) Assay presented at a symposium at the International Society of Blood Transfusion (ISBT) meeting in Edinburgh. The data, presented by Dr. Claudio Velati
Boehringer Ingelheim Reports Tipranavir Safety and Pharmacokinetics Data at International AIDS Conference - Interim Results Presented of First HIV Drug Development Program to Examine Dual-Boosted PI Therapy in Highly Treatment-Experienced Patients: PRNewswire - July 14, 2004; BANGKOK, Thailand , July 14 /PRNewswire/ -- Boehringer Ingelheim today announced new, interim findings from a Phase IIb study of tipranavir, a non-peptidic protease inhibitor, in HIV-positive patients with limited treatment options. The four-week results demonstrate that tipranavir is well tolerated when boosted with
Panacos Pharmaceuticals Presents Phase 1 Clinical Data on First-in-Class HIV-1 Maturation Inhibitor, PA-457, at XV International AIDS Conference, Bangkok, Thailand: PRNewswire - July 14, 2004; -- Additional Panacos Presentations Include Data on PA-457 s Molecular Target and the Discovery of Novel HIV Fusion Inhibitors GAITHERSBURG, Md., July 14 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today provides results of a recently completed Phase 1 clinical trial of its lead HIV drug candidate, PA-457, at the XV
Lower Frequency of Moderate to Severe Drug-Related Diarrhea Associated With LEXIVA Compared to Nelfinavir in Treatment-Naive HIV Infected Adults: PRNewswire - July 14, 2004; BANGKOK, Thailand , July 14 /PRNewswire/ -- The frequency of moderate to severe drug-related diarrhea was significantly lower in HIV-infected patients taking the protease inhibitor (PI) LEXIVA(R) ( fosamprenavir calcium) compared to those taking the PI nelfinavir (NFV), according to 48-week data from SOLO and NEAT stu
Kaletra(R) (lopinavir/ritonavir) Based Regimens Demonstrate Favorable Resistance in Clinical Trials: PRNewswire - July 14, 2004; BANGKOK, Thailand , July 14 /PRNewswire-FirstCall/ -- In two clinical studies, no primary protease inhibitor (PI) resistance was reported in antiretroviral-naive patients taking a Kaletra (R) ( lopinavir / ritonavir
CytRx Corporation, Advanced BioScience Laboratories and University of Massachusetts Announce First Patients Enrolled in HIV Vaccine Trial: PRNewswire - July 14, 2004; LOS ANGELES, July 14 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced today that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine develo
REYATAZ(R) (atazanavir sulfate) Granted Approval For Use With Low-Dose Ritonavir in Treatment-Experienced HIV-Infected Patients - Package Insert to Include 48-Week Data Comparing Regimen Containing REYATAZ/Ritonavir to Kaletra(R) -: PRNewswire - July 14, 2004; PRINCETON, N.J., July 14 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that REYATAZ(R) ( atazanavir sulfate) has received approval from the U.S. Food and Drug Administration ( FDA ) to include new scientific data and dosing in its package insert, or label
Epimmune Presents Preliminary HIV Clinical Trial Data at XV International AIDS Conference in Bangkok: PRNewswire - July 13, 2004; SAN DIEGO, July 13 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today presented early data from one of the ongoing Phase I trials of its EP HIV-1090 therapeutic vaccine (EP1090) for HIV-infected patients. The available data were summarized in a poster presentation at the XV International AIDS Conference in Ba
New Invirase(R) Data Demonstrate Undetectable Viral Load in 91% of Patients; Clinical trial demonstrates high potency combined with good tolerability: PRN